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Abstract 
 
Histone deacetylases (HDACs) are a family of enzymes regulating the acetylation level of 
histones as well as non-histone proteins and, thus, controlling gene activity. HDACs 
remove acetyl groups from histone tails, thereby acting as co-repressors of gene 
transcription. The functions of HDACs have been extensively studied in vitro and suggest 
important roles of HDACs in differentiation processes in vivo and in embryonic 
development in particular. However, the role of the different classes of HDACs in 
controlling developmental processes remains to be fully elucidated. In particular, our 
knowledge of the functions of class I HDACs (HDACs 1, 2, 3, and 8) during development 
is limited. This study has addressed the role of class I HDACs in cardiac development of 
the avian model organism “chicken” during early embryonic stages. Heart development 
is a complex and precisely controlled developmental process. Because of this 
complexity, the heart is the organ system with the highest congenital malformation rate 
in humans. In most cases, the role of class I HDACs during cardiac development has so 
far been inferred by analysis of conditional knock-out mice showing multiple heart 
malformations at birth. Due to a previously published study, the temporal expression 
patterns of HDACs 1, 2, 3, and 8 in the chick heart are known. Thus, to gain insight into 
the activities of class I HDACs in cardiac tissue, these enzymes were inhibited by 
Trichostatin A (TSA), a chemical inhibitor of HDACs. The inhibitor was applied to the 
hearts by implantation of acrylic beads soaked in TSA or by direct injection into the 
pericardial cavity. Subsequent histological and morphometric analysis, a proliferation 
assay (BrdU assay) as well as an apoptosis assay (TUNEL assay), and the determination of 
the acetylation level in the chick hearts by Western analysis allowed first insights into 
phenotypic effects of class I HDAC inhibition in avian cardiac tissue. The examined 
chicken hearts treated with the HDAC inhibitor displayed a range of severe phenotypes, 
such as atrial hypertrophy, ventricular hypertrophy, hypertrophy of the right ventricle, 
malformations of the ventricular septum, and aberrant formation of the outflow tract. 
However, the cardiac tissue showing hypertrophic effects, especially atrial hypertrophy, 
was found to be more pronounced than the other phenotypes. These findings offer a 
basis for further functional analysis of class I HDACs in cardiac development. 
Additionally, this study presents experimentations which were performed in embryonic 
chicken hearts for the first time; hopefully this piece of work provides possibilities for 
the development of novel manipulation procedures regarding the model system 
“chicken”. 
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Zusammenfassung 
 
Histondeacetylasen (HDACs) sind eine Familie von Enzymen, die den Acetylierungslevel 
von Histonen und auch anderen Proteinen regulieren und so die Genaktivität 
kontrollieren. HDACs entfernen Acetylgruppen von Histonschwänzen, weswegen sie als 
Co-Repressoren der Gentranskription agieren. Die Funktionen von HDACs wurden 
ausführlich in vitro studiert und es wird angenommen, dass HDACs in in vivo 
Differenzierungsprozessen und im Speziellen in der Embryonalentwicklung eine wichtige 
Rolle spielen. Die Rollen der verschiedenen Klassen von HDACs in der Kontrolle von 
Entwicklungsprozessen müssen aber noch vollständig aufgeklärt werden. Insbesondere 
unser Wissen über die Funktionen von Klasse I HDACs (HDACs 1, 2, 3 und 8) während der 
Entwicklung ist begrenzt. Diese Studie hat die Rolle von Klasse I HDACs in der 
Herzentwicklung des Modellorganismus „Huhn“ während früher embryonaler Stadien 
zum Thema. Die Herzentwicklung ist ein komplexer und präzise gesteuerter 
Entwicklungsprozess. Aufgrund dieser Komplexität ist das Herz beim Menschen das 
Organsystem mit der höchsten Rate an angeborenen Missbildungen. In den meisten 
Fällen wurde die Rolle von Klasse I HDACs während der Herzentwicklung bisher anhand 
von Analysen konditioneller Knock-out Mäuse, die bei der Geburt mehrere Herzfehler 
zeigten, interpretiert. Durch eine vor Kurzem publizierte Studie sind die zeitlichen 
Expressionsmuster der HDACs 1, 2, 3 und 8 im Hühnerherzen bekannt. Um Einblicke in 
die Aktivitäten von Klasse I HDACs im Herzgewebe zu gewinnen, wurden diese Enzyme 
durch Trichostatin A (TSA), einem chemischen HDAC-Hemmer, inhibiert. Der Inhibitor 
wurde durch die Implantation von in TSA getränkten Acrylbeads oder durch direkte 
Injektion in die Perikardhöhle in das Herz eingebracht. Die nachfolgende histologische 
und morphometrische Analyse, ein Proliferationsassay (BrdU-Assay) als auch ein 
Apoptoseassay (TUNEL-Assay) und die Bestimmung des Acetylierungslevels in den 
Hühnerherzen durch eine Western-Analyse erlaubte erste Einblicke in phänotypische 
Effekte, die durch Hemmung der Klasse I HDACs im Herzgewebe von Vögeln entstanden 
sind. Die untersuchten Hühnerherzen, die mit dem HDAC inhibitor behandelt wurden, 
zeigten eine Reihe von schweren Phänotypen, wie atriale Hypertrophie, ventrikuläre 
Hypertrophie, Hypertrophie des rechten Ventrikels, Fehlbildungen des Ventrikelseptums 
und aberrante Formation des Ausflusstraktes. Die Herzen, die hypertrophe Effekte 
zeigten, insbesondere jene mit atrialer Hypertrophie, waren ausgeprägter als die 
anderen Phänotypen. Diese Ergebnisse bieten eine Basis für weitere funktionelle 
Analysen von Klasse I HDACs in der Herzentwicklung. Außerdem präsentiert diese Studie 
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Experimente, die am embryonalen Hühnerherzen das erste Mal durchgeführt wurden; 
diese Arbeit soll Möglichkeiten für die Entwicklung neuer Manipulationsverfahren im 
Hinblick auf das Modellsystem „Huhn“ bieten. 
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1. Introduction 
1.1. The epigenetic mark 
Every multicellular organism consists of a considerable number of various cell types, 
each of them displaying a unique profile of gene expression which can be altered in 
response to physiological signals being caused by environmental influences. The 
modification of gene expression patterns is strongly affected by transcriptional 
regulation; transcriptional regulatory factors bind reversibly to amino-acid residues 
within histone tails changing chromatin structure and therefore regulating gene 
transcription. The effect can be an activating one or a repressive one. (Allis et al., 2009; 
Haberland et al., 2008) 
Histones are alkaline proteins consisting, as all other proteins do, of amino acids. These 
proteins are organized in two super-families: core histones (H2A, H2B, H3, and H4) and 
linker histones (H1 and H5).  The four core histones form a so called histone octamer 
comprising of two H2A-H2B dimers and one H3-H4 tetramer; around each octamer 147 
base pairs of DNA are wrapped forming a nucleosome. The linker histone H1 is 
associated to the nuclesome and binds to the entry and exit sites of the DNA securing it 
into place, thus enabling higher order structures.  
The four core histones are highly conserved through evolution and share a comparably 
similar structure, including a so called histone tail protruding from the N- or amino 
terminus of the protein. The histone tail holds several possibilities of being covalently 
modified; it is the site of posttranslational modifications. (Allis et al., 2009) 
The most widespread posttranslational modifications include methylation, 
phosphorylation and acetylation (Strahl & Allis, 2000); such modifications enable, like 
mentioned above, environment-cell interaction via linking extracellular signals with the 
genome (Allis et al., 2009; Haberland et al., 2008). 
The collaboration of several histone modifications is implied to establish a so called 
“histone code” which expands the one-dimensionality of the primary DNA sequence; as 
a result the functional plasticity of the eukaryotic genome is increased. (Jenuwein & 
Allis, 2001) 
 
1.1.1. Histone acetylation and deacetylation 
Histone acetylation and deacetylation are contradictory processes; they regulate gene 
transcription by locally altering the electric charge of the histone, thereby affecting the 
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chromatin structure and the accessibility for the transcription machinery (Allis et al., 
2009; Gregoretti et al., 2004). 
For the histones being destined to pack the negatively charged DNA into chromatin, the 
surface of the proteins is rich with amino acids containing side chains with a positive 
charge, like lysine and arginine. Concerning acetylation, there were only found 
acetylated lysines up to now (Allis et al., 2009). If lysine residues within histone tails 
become acetylated, the positive charge of the amino acid is neutralized, hence, the 
attraction between the negative charge of the DNA and the positive charge of the 
histone is reduced and the structure of the chromatin relaxes; the accessibility for the 
transcription machinery to the target genes grows and the genes become activated 
(Brunmeir et al., 2009; Shahbazian & Grunstein, 2007). In addition, bromodomain 
proteins bind to acetylated histones and function as transcriptional activators 
(Ruthenburg et al., 2007). 
On the contrary, the deacetylation of histones promotes the opposite effect; the 
elimination of acetyl moieties leads to chromatin condensation followed by repression 
of transcription (Brunmeir et al., 2009; Shahbazian & Grunstein, 2007). 
 
1.1.2. Histone deacetylases influence gene expression 
 
Histone acetylation and deacetylation are regulated by histone acetyltransferases 
(HATs) and histone deacetylases (HDACs). These two enzyme families act as antagonists; 
hence histone acetylation is a reversible process. HATs acetylate histone tails, therefore, 
locally opening the chromatin and enabling activation of target genes as described 
above. Considered as transcriptional co-repressors, HDACs act contradictory; they 
remove acetyl groups from histone tails (Allis et al., 2009; Brunmeir et al., 2009; 
Shahbazian & Grunstein, 2007) causing chromatin compaction and aggravated 
transcription (Allis et al., 2009; Murko et al., 2010; Shahbazian & Grunstein, 2007). 
Moreover, besides histones HDACs also deacetylate non-histone proteins like 
transcription factors (e. g. p53, E2F1, and YY1) and tubulin, a protein of the cellular 
cytoskeleton (Brunmeir et al., 2009). 
In addition to their role in histone acetylation and deacetylation, both, HATs and HDACs, 
influence the affinity of acetyl-histone binding factors. These enzymes act as key factors 
of the regulatory mechanism for gene expression, playing a considerable role in the 
determination of the cell-fate of multicellular organisms during embryogenesis. (Murko 
et al., 2010) 
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HDACs are unable to bind directly to the DNA; their influence on the chromatin 
structure depends on their corroboration with chromatin-binding proteins like 
transcriptional activators and repressors which ensure the HDACs’ recruitment to target 
genes. Another possibility to exert their influence is the anticipation of HDACs in 
multiprotein transcriptional complexes (Brunmeir et al., 2009; Haberland et al., 2008; 
Shahbazian & Grunstein, 2007); the specificity and biological reactions of HDAC 
recruitment depend on the assembly of the complex (Brunmeir et al., 2009). Hence, 
concerning the modulation and regulation of individual gene programmes displayed in 
defined cell types of multicellular organisms, the effect and specificity of HDACs 
correlate with the identity, the attainable binding partners and the signalling milieu of 
the cell (Haberland et al., 2008). Within such a multiprotein complex one task of HDACs 
may be the preparation of target genes; the acetyl marks have to be detached from the 
chromatin before new modifications (e. g. histone methylation) established by other 
proteins of the same complex, can take place (Brunmeir et al., 2009). 
Inhibition or delition of Hdacs generally leads to up- or downregulation of gene 
expression (Haberland et al., 2008; Montgomery et al., 2007). 
 
1.1.3. The HDAC superfamily 
 
The HDAC superfamily is ancient and wide in range (Brunmeir et al., 2009; Haberland et 
al., 2008; Murko et al., 2010). The 11 classic HDACs encoded by the mammalian genome 
are categorized into three classes due to sequence similarities: class I (HDAC1, HDAC2, 
HDAC3, and HDAC8), class II (HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, and HDAC10), and 
class IV (HDAC11-like). Moreover, the mammalian genome also encodes class III HDACs, 
which are also addressed as sirtuins; these are NAD-dependant Sir2-like acetylases 
derived from Saccharomyces cervisiae being functionally unrelated to the classic HDACs 
(Allis et al., 2009; Gregoretti et al., 2004). 
Class II HDACs are reported to be separable into two subclasses: HDAC4, HDAC5, HDAC7, 
and HDAC9 are summarized as class IIa HDACs and class IIb contains HDAC6 and HDAC10 
(Yang & Seto, 2008). 
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1.2. Class I HDACs 
 
The class I HDAC family comprises of HDAC1, HDAC2, HDAC3, and HDAC8, which are 
expressed ubiquitously throughout the organism, primarily accumulated in the cell 
nuclei; these proteins demonstrate a high enzymatic activity towards histone substrates 
(Haberland et al., 2008; Murko et al., 2010). 
All class I HDACs consist of an evolutionarily conserved catalytic domain which includes 
more than 300 amino acids; thus, this domain takes an extensive part of the protein 
(Brunmeir et al., 2009; Haberland et al., 2008). The catalytic domain is called histone 
deacetylase domain (HDAC domain). It is composed of a pocket holding certain charged 
and uncharged amino acids which interact with a zinc ion as a charge-relay system; 
hence, the HDAC domain is important for the enzymatic function of the protein. 
(Brunmeir et al., 2009) 
In human HDAC 1 comprises of 482 amino acids; HDAC2 obtains 488 amino acids. HDACs 
1 and 2 include a HDAC association domain (HAD) formed by the first ~50 amino acids of 
the N-terminus of the protein, which partly overlaps with the HDAC domain reaching 
from residues ~10 to ~320; the HAD is required for protein-protein interaction enabling 
homo- and heterodimerisation. (Brunmeir et al., 2009) 
The C-terminal portion of class I HDACs is more specific and contains characteristic 
domains dependent on the HDAC isoform. HDAC1 includes a C-terminal nuclear 
localisation signal (NLS); in contrast, HDAC 2 holds a coiled-coil domain at its C-terminus 
for probable further protein-protein interaction.  (Brunmeir et al., 2009) 
HDAC3 consists of 428 amino acids in human. As in HDACs 1 and 2 the catalytic HDAC 
domain of HDAC3 is localized in the conserved N-terminal part of the protein reaching 
from amino acids 3 to 316 (Escaffit, 2007). The first 122 N-terminal residues of HDAC3 
form a sequence which enables oligomerization of the protein with itself (Yang et al., 
2002); this region seems to be crucial for cell viability of DT40 cells (Takami & Nakayama, 
2000). The last 27 amino acids at the C-terminal end of HDAC3 are necessary for histone 
deacetylation and, consequently, for transcriptional repression. It is thought possible, 
that deletion of this C-terminally sequence alters the protein’s global conformation and 
causes inactivity of the HDAC domain. Besides obtaining a NLS at its C-terminus, ranging 
from residues 313 to 428, HDAC3 also acquires a nuclear export signal (NES) which 
streches from amino acids 180 to 313; thus, HDAC 3 can be accumulated not only in the 
cell nucleus, but also in the cytoplasm. It is supposed that the equilibrium between the 
NLS and the NES is determined by the cell type and by environmental conditions. (Yang 
et al., 2002) 
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Human HDAC8  is composed of 377 amino acids. The central region of HDAC8, 
containing the catalytic domain with an NLS in its center, shows high similarity to the 
other class I HDACs; this part of the proteins is evolutionarily highly conserved. (Buggy et 
al., 2000; Hu et al., 2000; Van den Wyngaert et al., 2000) Conversely, amino acids 1 to 34 
of the N-terminus and residues 348 to 377 of the C-terminus of HDAC8 are significantly 
distinct from the other members of the class I HDAC family; for these areas of the 
protein a specific role for HDAC8 is suggested (Van den Wyngaert et al., 2000). In 
addition, the C-terminal end of HDAC8 is shorter than the C-termini of HDACs 1 to 3 
(Buggy et al., 2000). HDAC 8 includes a region containing mostly acidic amino acids 
(residues 83 to 95) which is not existent in the other class I HDACs; this domain is 
implied to be important for protein-protein interactions (Van den Wyngaert et al., 
2000). For the expression of Hdac8 in humans, two variants of transcripts were found 
(Buggy et al., 2000; Hu et al., 2000; Van den Wyngaert  et al., 2000); concerning these 
transcripts differing in size, there are conflicting data: Buggy et al. (2000) detected 
transcripts of 1.7 kb and 2.4 kb, Hu and collegues (2000) observed 2.0 kb and 2.4 kb 
transcripts and Wyngaert et al. (2000) discovered RNA of 2.0 kb and 2.2 kb. These two 
RNA versions are suggested to be tissue-specific splice variants of HDAC8 (Van den 
Wyngaert et al., 2000) and are possibly playing a role in tumour cell lines (Buggy et al., 
2000; Hu et al., 2000; Van den Wyngaert  et al., 2000). 
Futhermore, all class I HDACs are targets for posttranslational alterations themselves; 
modifications such as phosphorylation, acetylation and sumoylation are suggested to 
affect the stability of the protein, its enzymatic activity, nuclear import and the 
generation of complexes (Brunmeir et al., 2009). 
HDAC1 and HDAC2 are built very similarly (Brunmeir et al., 2009; Haberland et al., 2008; 
Murko et al., 2010); in human they share 82% identity on the protein level; it is 
suggested that Hdacs 1 and 2 are derived from a single ancestral gene which became 
duplicated within the vertebrate lineage (Brunmeir et al., 2009). The two enzymes 
mostly anticipate in repressive complexes like the Sin3 corepressor complex, the 
nucleosome remodelling and deacetylase complex (NuRD), the CoREST complex, the 
Polycomb repressive complex (PRC2) (Brunmeir et al., 2009; Haberland et al., 2008; 
Murko et al., 2010), the Nanog and Oct4 associated deacetylase complex (NODE), the 
SHIP1 containing complex (Brunmeir et al., 2009; Murko et al., 2010), and the BRAF-
HDAC complex (BHC) together (Brunmeir et al., 2009). 
With 34%-39% amino acid identity (Buggy et al., 2000; Hu et al., 2000; Van den 
Wyngaert et al., 2000), in human HDAC3 is most similar to HDAC8; hence, these both 
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proteins are evolutionary most closely related (Buggy et al., 2000; Hu et al., 2000). 
HDAC3 partly coincides with HDACs 1 and 2 as well: The HDAC3 sequence reaching from 
residues 181 to 333 was compared to the corresponding regions of HDAC1 and HDAC2; 
HDAC3 shares only ~68% identity with either HDAC1 or HDAC2. (Examining these 
corresponding sequences in HDACs 1 and 2, they yield 93% identity.) (Yang et al., 2002) 
Additionally, HDAC3 can be detected in quite different complexes, such as the N-CoR-
SMRT complex (Haberland et al., 2008; Murko et al., 2010) indicating specific biological 
functions of HDAC3 in comparison to the other members of class I HDACs (Murko et al., 
2010). 
Thus, HDACs 1, 2, and 3 can serve as catalytic subunits in multiprotein complexes 
cooperating with DNA sequence-specific transcription factors in order to inhibit 
transcription or interact with other chromatin modifying factors to form epigenetic 
programs (Murko et al., 2010). 
Being phylogenetically analysed, HDAC8 was found to be a novel member of class I 
HDACs which can only be detected in vertebrates. The ancestral genes (orthologs) 
encoding for HDAC1-, HDAC2-, and HDAC3-like proteins already appear in Drosophila 
melanogaster. (Brunmeir et al., 2009) 
Concerning the similarity of HDAC 8 to the other members of the class I HDAC family, 
there exist contradictory results for their relatedness in human: Buggy and colleagues 
(2000) suggest that HDAC8 and HDAC1 share 31% amino acid identity, with HDAC2 it 
shares 30% identity and 34% of the amino acid sequence of HDAC3 are identical to the 
sequence of HDAC8 (Buggy et al., 2000). Hu et al. (2000) propose 37% of HDAC8 to be 
identical with HDAC3, and with HDAC1 the protein shares as well 37% protein sequence 
identity (Hu et al., 2000). The laboratory of Van den Wyngaert et al. (2000) implies a 
54% sequence similarity of HDAC8 to HDACs 1 and 2; with HDAC3 the enzyme shares 
39% identity on the protein level (Van den Wyngaert et al., 2000). 
For the anticipation of HDAC8 in a complex, there has been found no evidence so far 
(Haberland et al., 2008; Murko et al., 2010; Yang & Seto, 2008). 
 
1.2.1. The role of class I HDACs during embryogenesis 
 
The observation of all model systems studied so far showed results of expression of class 
I HDACs during most developmental stages in numerous different cell types. 
Based on the evidence of being highly homologous, ubiquitously expressed, and being 
highly active towards common substrates,  all class I HDACs are concluded to being 
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functionally redundant in vivo. Nevertheless, studies in knockout mice lacking Hdac 
genes showed that each single HDAC takes an individual part in the regulation of specific 
gene expression programs (Haberland et al., 2008; Murko et al., 2010). 
In Hdac1-null mice Lagger et al. (2002) observed general growth retardation and serious 
proliferation defects leading to lethality before embryonic day 10.5 (E10.5) (Lagger et 
al., 2002). Furthermore, HDAC1 has been determined to target many genes playing a 
role in development and differentiation. Consequently, further examinations of the 
origin of Hdac1-null phenotypes are necessary. (Brunmeir et al., 2009) 
Proliferation defects are also examined in embryonic stem cells lacking HDAC1; due to 
significantly decreased HDAC activity histones H3 and H4 become moderately 
hyperacetylated (Lagger et al., 2002; Zupkovitz et al., 2006) causing an upregulation of 
expression in about 4% of the genes, but also a downregulation in 3% of the genes. 
Subsequently, in embryonic stem cells HDAC1 is a vital deacetylase regulating individual 
gene expression profiles by activation or repression of specific promoters. (Zupkovitz et 
al., 2006) 
Nevertheless, Montgomery et al. (2007) found out that a tissue-specific delition of 
Hdac1 in the heart, brain and skeletal and smooth muscles is surprisingly well tolerated 
in the model system mouse. These findings are attributed to probable redundant effects 
of HDAC1 and HDAC2 (Montgomery et al., 2007). 
In zebrafish a knockout of hdac1 leads to lethal skeletal and neuronal defects (Nambiar 
et al., 2007). 
Concerning Hdac2-null mice, two independently performed investigations maintained 
conflicting results. Montgomery et al. (2007) found that a global deletion of Hdac2 in 
vivo resulted in perinatal affliction with severe cardiac defects leading to the death of 
the mice within the first 24 hours after birth. (Montgomery et al., 2007; Haberland et al., 
2008; Murko et al., 2010) Hence, whereas Hdac1-null mice show an obvoius phenotype 
and early prenatal lethality, a global Hdac2 delition causes no apparent phenotype in 
early development; however, the whole murine Hdac2-null offspring died within 24 h 
after birth (Montgomery et al., 2007). Therefore, it is suggested that HDAC1 particularly 
regulates a variety of essential target genes during embryogenesis or, supporting the 
redundancy thesis about HDACs 1 and 2 (described in the last paragraph of this chapter), 
that the quantity of expressed HDAC2 cannot compensate for the deficiency of HDAC1. 
Accordingly, in ES cells the expression level of HDAC1 is considerably higher than that of 
HDAC2 (Seiser, C., unpublished data). (Brunmeir et al., 2009) 
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In contrast to the complete lethality of Hdac2-null mice, Trivedi et al. (2007) found that 
mice being homozygous for a lacZ insertion in Hdac2, which was meant to generate a 
null mutation, showed a less severe phenotype: For half of the animals the gene 
disruption led to lethality within 25 days after birth. The other half of the mice, which 
survived, were smaller and and suffered from a lack of vitality and energy (lethargy); 
after 2 months they had recovered and developed normally. (Trivedi et al., 2007) 
Possibly varying genetic backgrounds of the tested mice in the 2 previously described 
studies provide an approach to these differing outcomes. Another feasible explanation 
would be that the lacZ insertion in Hdac2 did not create a definite null allele but a 
hypomorphic allel; subsequently, Hdac2 would be expressed sufficiently and enable 
viability. (Haberland et al., 2008; Murko et al., 2010) 
In mice lacking HDAC3 in the germ line, defects in gastrulation induce a lethal embryonic 
phenotype dying by E9.5 (Montgomery et al., 2008). 
A conditional deletion of Hdac3 in the liver (Knutson et al., 2008) and the heart of a 
mouse embryo caused an increased lipid accumulation in these organs (Knutson et al., 
2008; Montgomery et al., 2008). If the disrupted fatty-acid intake and metabolism 
concerned the heart, the mouse died after 3-4 months after birth (Montgomery et al., 
2008). 
In zebrafish the observation of morpholino-mediated knockdown of hdac3 mRNA 
showed disturbed formation and growth of the liver (Farooq et al., 2008). 
Hdac8-null mice suffer from a highly specific deficiency of cranial neural crest cells 
causing skull instability, finally leading to perinatal lethality (Haberland et al., 2009). 
 
HDAC1 and HDAC2 – working together or individually? 
Sharing the highest similarity within class I HDACs, their proposed common ancestral 
origin and their joint participation in repressive multiprotein complexes, suggest 
redundant roles for HDACs 1 and 2. In contrast, several studies (as described above) 
report severe phenotypes after deletion of either Hdac1 or Hdac2 pointing to individual 
roles of the two enzymes in organisms containing both genes. 
This implication is supported by a recent study reporting about spatially separated 
expression domains of Hdac1 and Hdac2 in the neural tube of a mouse embryo at stage 
E11.5. Hdac1 expression was observed to be restricted to the inner ependymal layer of 
the neural tube (determined to become certain epithelial cells lining the brain ventricles 
and the central canal of the spinal cord), whereas transcripts of Hdac2 were exclusively 
found in the middle cell layer, also called mantle layer (destined to generate the gray 
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matter of the CNS). (Murko et al., 2010) A current study about neuro-glial development 
in the CNS of the mouse conforms to these findings (MacDonald & Roskams, 2008). 
Thus, the preclusive Hdac1 and 2 expression profiles in the central nervous system of 
the vertebrate model organism indicate that the two enzymes may act independently in 
specific cell-autonomous ways. Being ignorant to this suggestion, in mice with a specific 
deletion of either Hdac1 or Hdac2 in two different cell types of the CNS no distinct 
phenotype was observable; only a total lack of both enzymes affects death after birth. 
Taking all these findings into account, the suggestion of cross-regulation beyond the cell 
type has been arisen, however, to date remains to be elucidated. (Murko et al., 2010) 
Occasionally, closer observations of the actions of the two HDACs in several mouse 
tissues and cell lines showed that a depleted expression level of one of both genes 
provoked a rise in the expression quantity of the other gene; the inactivation of Hdac1 
induces the upregulation of Hdac2 expression and vice versa. Accordingly, the various 
phenotypes associated with either Hdac1 or Hdac2 deficiency are possibly caused by the 
increasing expression level of its paralog and not necessarily because of the silencing of 
the gene itself. (Brunmeir et al., 2009) Regarding this issue, Zupkovitz et al. (2006) 
performed gene expression studies in mouse ES cells; they found out that the effects of 
Hdac1 deletion on the transcription of definite target genes can be quite inconsistent: In 
some cases HDAC2 cannot compensate for the loss of Hdac1 expression, subsequently, 
the expression of numerous genes becomes induced. On the contrary, it is also possible 
that genes are transcriptionally repressed due to the escalated expression level and 
ectopic recruitment of HDAC2 to gene promoters. (Zupkovitz et al., 2006) 
 
1.2.2. Cardiac functions and phenotypes of class I HDACs 
 
As described in the previous chapter, a conditional deletion of Hdac1 in the heart of a 
mouse embryo is well tolerated (Montgomery et al., 2007). 
On the contrary, a global deletion of Hdac2 in the same model organism causes lethality 
24 hours or within 25 days after birth due to severe cardiac aberrations. Both 
laboratories (Montgomery et al., 2007; Trivedi et al., 2007) associated the observed 
obliteration of the right ventricular chamber due to uncontrolled proliferation of 
ventricular cardiomyocytes  and the unusually slow heartbeat (bradycardia) with the 
postnatal death of the animals. (Montgomery et al., 2007; Trivedi et al., 2007) 
Kook et al. (2003) demonstrated the interaction of HDAC2 with the homeodomain-only 
protein (HOP), which regulates cardiomyocyte proliferation and growth in an activating 
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or repressive way. They propose that HOP recruits HDAC2 to anticipate together in a 
repressive transcription complex controlling cardiac growth during mouse 
embryogenesis. The ability of HOP to associate with HDAC2 results in transcriptional 
repression of antihypertrophic genes; thus, overexpression of HOP induces cardiac 
hypertrophy (which means an escalated cell size for the same cell number) and fibrosis 
(i. e. the formation of additional fibrous connective tissue) leading to embryonic 
lethality. Overexpression of a mutant form of Hop, unable to recruit HDAC2, as well as 
HDAC inhibitors, as Trichostatin A (TSA), prevent hypertrophy of the heart. (Kook et al., 
2003) Another possibility to weaken hypertrophic effects in cardiomyocytes is the 
deletion of Hdac2; although Hop was overexpressed, the examined murine hearts 
displayed no hypertrophy (Trivedi et al., 2007). In contrast, a tissue-specific 
overexpression of either Hdac1 or Hdac2 in the hearts of mice showed severe cardiac 
hypertrophy and dilatation resulting in sudden death of the animals (Montgomery et al., 
2008; Trivedi et al., 2007). 
Trying to find out, if the lethal phenotype of Hdac2-null mice demonstrates a cell-
autonomous function of HDAC2 in cardiac myocytes, Montgomery and colleagues (2007) 
conditionally deleted Hdac2 in murine cardiomyocytes. Surprisingly, the conditional 
deletion of the gene in mice hearts (and other tissues like brain, endothelial cells, 
smooth muscle, and neural crest cells) was as well tolerated as the cardiac conditional 
deletion of Hdac1; a deletion of either of these two in specific tissues displayed no 
definite phenotypes. As the severe heart defects displayed in the mice suffering from a 
global deletion of Hdac2, could not be observed in the viable animals bearing a cardiac 
conditional Hdac2 deletion, Montgomery et al. (2007) consider HDAC2 to play an 
essential role in various cardiac cell lineages. (Montgomery et al., 2007) 
However, if both genes are deleted within the same tissue, serious effects are 
observable; hence, HDACs 1 and 2 are suggested to operate redundantly during later 
development of the embryo and throughout the lifetime of the adult organism 
(Haberland et al., 2008; Montgomery, et al., 2007). 
To obtain insight into the in vivo activities of these both enzymes and their redundance 
capacities, different experiments were performed. A conditional deletion of Hdac1 and 
Hdac2 in cells of the cardiac lineage revealed no obvious phenotype; a single wild-type 
allele of either of both Hdac genes ensures unaffected embryogenesis. On the contrary, 
a deletion of all Hdac1 and Hdac2 alleles causes an escalated expression of genes which 
encode calcium channels and skeletal muscle-specific contractile proteins in the heart; it 
is communicate that the up-regulated expression of calcium channel subunit genes 
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induces a pathological calcium inflow into cardiac myocytes which leads to dysregulated 
functions of sarcomeres affecting cardiac arrhythmias and dilated cardiomyopathy 
(represented by an enlarged and weakened heart not able to maintain an efficient 
ventricular systolic pump function) resulting in neonatal death. (Montgomery et al., 
2007) Concerning the severity of the phenotype, the time of deletion was reported to be 
crucial. In a mouse embryo at developmental stage E8.5 (embryonic day 8.5) a deletion 
of both Hdacs 1 and 2, in the cardiac tissue leads to death 2 days later; if the deletion 
occurs in the heart of a 10.5 day old embryo, the mouse postnatally lived for more than 
3 weeks. Thus, it was suggested that the severity of the phenotype decreases with the 
progression of development. (Haberland et al., 2008) 
Transcriptionally analysing these mice showed that deleting Hdac1 and Hdac2 in the 
heart induces specific gene cascades which exert influence on the Ca2+ ion handling and 
the contractility of cardiac cells; the upregulation through derepression involved 0.94% 
of transcripts (162 genes) and 0.58% of the transcriptome (100 genes) were down-
regulated. Further analysis demonstrated an inappropriate up-regulation of calcium 
channel subunit genes and skeletal muscle contractile protein genes. (Montgomery et 
al., 2007) The expression of several calcium channels and skeletal muscle-specific 
contractile proteins in the embryonic cardiac tissue is transcriptionally regulated by the 
interaction of neuron-restrictive silencer factor (NRSF) (Kuwahara et al., 2003) with class 
I HDACs and HDACs 4 and 5 (class IIa HDACs) (Nakagawa et al., 2006). If NRSF is, due to a 
mutation, incapable of recruiting proteins with repressive deacetylase activity, the 
transcription of genes anticipating in calcium flux and contractility becomes activated 
resulting in cardiac defects and lethality as described above (Kuwahara et al., 2003; 
Montgomery et al., 2007). Consequently, a deletion of Hdacs 1 and 2 within a cell 
creates the same effects because NRSF and also other transcription factors fail to form a 
repressive complex (Haberland et al., 2008). However, Montgomery et al. (2007) imply 
that the up-regulation relates not only to genes controlled by NRSF; HDACs 1 and 2 are 
suggested to repress certain genes involved in cardiac contractility by an NRSF-
independent mechanism (Montgomery et al., 2007). 
After taking all these data into account, HDAC1 and HDAC2 were found to have crucial 
functions within cardiac development, in which the enzymes seem to work partially 
redundantly (Brunmeir et al., 2009). 
As mentioned in the previous chapter, a conditional delition of Hdac3 in a mouse heart 
results in an affecting ligand-induced increase of lipids within the organ ending in 
lethality after 3-4 month after birth; examining the heart at this point of time, a severe 
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hypertrophy with enlarged right and left atria was observable. In the heart the gene 
programs regulating fatty-acid intake and metabolism are influenced by a nuclear 
receptor protein called peroxisome proliferator-activated receptor alpha (PPARα) which 
acts as a transcription factor controlling gene expression. The absence of the repressive 
HDAC3 causes a steep rise of PPARα activity being responsible for the subsequent 
metabolic disturbance. (Montgomery et al., 2008) 
Moreover, deletion of Hdac3 in the heart shows another phenotype; an escalated 
generation of collagen due to fibroblast proliferation leads to cardiac dysfunction 
(interstitial fibrosis) being phenotypically not dependent on increased action of PPARα. 
However, up to now it cannot be taken for granted that HDAC3 operates as a direct 
repressor of the transcription factors controlling the fibrotic gene cascade. 
(Montgomery et al., 2008) 
If Hdac3 is not deleted but over-expressed in the heart, the proliferation of 
cardiomyocytes increases without expansion of cell size (hyperplasia) causing enhanced 
thickness of the myocardium (Trivedi et al., 2008). 
Concerning the expression of Hdac8 in the heart, there exist opposing results. Buggy et 
al. (2000), Hu et al. (2000), and Van den Wyngaert et al. (2000), independently trying to 
detect Hdac8 expression sites, found low levels of Hdac8 mRNA in human cardiac tissue, 
whereas a more recent study reports about an exclusive Hdac8 expression in smooth 
muscle cells; no Hdac8 transcripts were observed in the heart (Waltregny et al., 2004). 
However, Wilson and colleagues (2010) demonstrated that in mice HDAC8 and sirtuin 1 
homolog (Sirt1; which is also a deacetylase) interact independently with the estrogen-
related receptor α (ERRα) in vivo; the enzymes enhance the transcriptional function of 
ERRα. The elimination of HDAC8 and Sirt1 reduces the affinity of ERRα to bind to the 
DNA. (Wilson et al., 2010) The ERRα belongs to the nuclear receptor superfamily 
regulating various target genes which encode for enzymes being involved in the 
maintenance of energy balance in animals; ERRα is one of the important regulators of 
endogenous lipid metabolism. In mice ERRα was found to be expressed at a high level in 
cardiac tissue (Ranhotra, 2009; Stein & McDonnell, 2006) because the heart prefers fatty 
acids as substrate for cellular energy production (Ranhotra, 2009). Hence, it may be 
possible that HDAC8 plays an indirect role in the energy metabolism of the heart via 
transcriptional regulation of ERRα; if Hdac8 is expressed in the mammalian heart 
remains to be fully elucidated.  
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1.3. Class I HDAC expression patterns during mouse and chick 
development 
 
Up to now several studies about in vivo functions of HDACs exist in mice; in other model 
systems results are rare. For that reason, I want to compare the expression sites of 
chicken embryos to that of mice during development, so that similarities and differences 
could be recognized more easily. 
A recent study of class I HDACs in chicken embryos provides new knowledge about the 
spatio-temporal expression pattern of HDACs 1, 2, 3 and 8 during the avian 
development. Additionally, the observations were compared to the quite different 
expression profile during mouse embryogenesis.  
Sequencing the chicken (Gallus gallus) genome demonstrated that it includes four genes 
being highly related to the mouse and human class I HDACs: Hdac1, Hdac2, Hdac3, and 
Hdac8. 
The homologies of class I HDACs full length protein sequences between chicken and its 
mouse equivalents were found to be even higher than the similarities of class I HDACs 
within the same species. (Murko et al., 2010) 
The expression of class I HDACs is considered to be omnipresent during embryogenesis. 
However, a recent review imparted fluctuating mRNA and protein levels between 
developmental stages and between species (Brunmeir et al., 2009; Murko et al., 2010). 
 
1.3.1. Expression levels during development 
 
Using qPCR, in chick embryos, Hdacs 1, 2, 3, and 8 were found to be expressed in a 
similar temporal pattern during the early stages of development (HH2-HH17). All class I 
HDACs showed highest expression levels during early gastrulation (HH2-3 correspond to 
6-13 hrs.), a subsequently weakening signal until reaching the lowest quantity at HH8-
HH11 (stages of neurulation; correspond to ~1.1-1.9 days), followed by another rise of 
protein expression. (Murko et al., 2010) Ma and Schultz (2008) gained similar results 
having performed experimentation in mouse preimplantation embryos; the embryos 
exhibited high expression levels of most class I HDACs at the blastocyste stage (Ma & 
Schultz, 2008). 
Hdacs 1 and 2 display high expression levels in mouse and can be detected throughout 
all prenatal developmental stages until birth and even in adulthood. Hdac2 mRNA is 
already observable in the fertilized oocyte and also HDAC1 protein can be identified in 
the nuclei of a two-cell stage embryo, in which the zygotic genes become just activated. 
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A maximum of Hdac1 expression was detected during gastrulation of the mouse 
embryo. (Brunmeir et al., 2009) 
In contrast, Zeng et al. (2004) were not able to observe a conclusive signal for HDAC8 in 
the preimplantation stages of mouse embryos (Zeng et al., 2004). However, during 
chicken embryogenesis Murko et al. (2010) already detected Hdac8 transcripts at the 
earliest developmental stage examined which was ~6-7 hours after incubation (HH2). 
(Murko et al., 2010) 
During later developmental stages Western Blot Analysis gave insight of class I HDAC 
expression levels throughout the embryo. For having the opportunity to compare chick 
and mouse development, corresponding stages of the embryogenesis of the two model 
organisms were observed: Chick HH13 (2-2.2 days) corresponds with mouse E10, chick 
HH17 (2.2-2.7 days) matches mouse E11.5 and HH25 (4.5 days) in chicken development 
is like E13 in mouse embryogenesis. 
In chicken Hdac1 levels of transcripts are low at developmental stages HH13 and HH17, 
subsequently intensifying at stage HH25. In contrast, during mouse embryogenesis a 
high degree of expression is already observed at stage E10 ensued by diminished levels 
at stages E11.5 and E13. Hdacs 2 and 3 display similar patterns during chick and mouse 
development with a nearly consistent expression level throughout the different 
embryonic stages. Hdac8, like Hdac1, shows contrasting trends on protein levels for 
chicken and mouse embryogenesis. Whereas the chicken embryo demonstrated a 
heightening accumulation of Hdac8 transcripts towards stage HH25, in the mouse 
embryo highest levels of protein expression were detected at stage E11.5 followed by a 
fast decline to a quantity barely perceptible at stage E13. (Murko et al., 2010) 
 
1.3.2. Spatio-temporal expression patterns 
 
All class I HDACs show overlapping expression patterns in chicken and mouse embryos. 
However, due to some species specific characteristics observed, individual roles of 
HDACs in embryogenesis must be taken into account. 
In both model organisms, mouse and chick, Hdacs 1, 2, 3, and 8 display a high level of 
expression in the brain vesicles, presenting a higher accumulation of transcripts in the 
prosencephalic areas and decreasing expression towards the rhombencephalic regions. 
In chicken embryos at developmental stage 12 according to Hamburger and Hamilton 
(1951) (HH 12) class I HDACs are expressed at sites of anterior and posterior neural tube 
closure; especially HDAC1 is detected. Moreover, during chick embryogenesis class I 
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HDACs seem to anticipate in the development of the neural crest, in parts of the sensory 
and the musculo-skeletal system, several internal organs and the branchial arches, 
which themselves hold a panoply of developmental capacities. These results were 
gained through whole mount in-situ hybridization (WMISH) by Murko and colleagues 
(Murko et al., 2010). 
 
Histone deacetylase 1 
During chicken development HDAC1 is first recognized as a faint signal in all three 
primary brain vesicles and the developing neural tube at stage HH10. Between HH10 
and HH13 a prominent expression in the brain and the open posterior part of neural 
tube, which is just about to close, is detected. After neural tube closure, the Hdac1 
protein level diminishes vigorously. Murko et al. (2010) suggest an important role of 
HDAC1 in neural tube closure. This thesis is supported by preliminary data, showing that 
a knock down of the enzyme at the expression hot spot results in neural tube closure 
defects. 
As development proceeds, the overall expression of Hdac1 is maintained, however, at a 
decreased level at stage HH17. This state of low transcript level is changed at HH25 with 
pronounced positive labelling in the face mesenchyme, the otic vesicles, and the wing 
and limb buds. 
The internal organs were the last to present Hdac1 expression. In the lung and liver 
anlagen low intensities of the enzyme were observable at stages HH17 and HH18; at 
stage HH25 (~4.5 days) the heart was found to show slight expression as well. (Murko et 
al., 2010) 
 
From embryonic day E10 to E13 the mouse embryo shows a similar spatial expression 
pattern of Hdac1 as the ortholog in the avian model system at stages HH10 and HH13; 
an expression signal is detected in the brain and in the caudal part of the neural tube 
being subjected to neural tube closure. A high expression of the enzyme is also 
observable in the otic vesicles, in the 4 developing limbs and in the branchial arches. 
Relating to the neural tube, Hdac1 expression was discovered to be restricted to the 
inner ependymal layer determined to become certain epithelial cells lining the 
cerebrospinal fluid-filled brain ventricles and the central canal of the spinal cord.  
In the internal organs, there was only found a weak positive labelling of the liver anlage 
at E11.5 and at E13 the genital tubercle showed expression of Hdac1. (Murko et al., 
2010) 
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Histone deacetylase 2 
Hdac2 expression in chick is first observable at HH12 in the forebrain and in otic and 
optic vesicles. At developmental stage HH14 the brain and the developing sensory 
organs remain positively stained; furthermore, the head mesenchyme, the first 
branchial arch, the notochord and growth zones like somites and the tail bud display 
Hdac2 expression.  The prominent positive labelling of the brain and head area and the 
otic and optic vesicles is sustained from stages HH18 to HH24; at stage HH19 a high 
expression level is also perceptible in all branchial arches, the neural crest cells, the wing 
and limb buds. 
In the internal organs the first expression of Hdac2 is observed in the nephric ducts at 
stage HH12 and remains at HH14 and HH15. Further on, at about day 4 of 
embryogenesis, a high expression rate of the enzyme is observed in the lung buds. No 
perceptive signal of HDAC2 was found in the developing heart of the chick. 
In the mouse embryo Hdac2 expression is detected in the brain and spinal cord at all 
developmental stages observed (E10 to E13). Concerning the neural tube, transcripts of 
Hdac2 are exclusively found in the middle cell layer, also called mantle layer which is 
destined to generate the gray matter of the CNS. Compared to the expression site of 
Hdac1 within the neural tube, the expression domains of both enzymes in the spinal 
cord are obviously spatially separated; the suggestion of functional redundancy is 
questioned. However, in the chicken embryo Hdacs 1 and 2 revealed an overlapping 
expression pattern in the spinal cord, where the enzymes are accumulated at low levels 
at developmental stage HH25 (the equivalent of E13 in mouse embryogenesis). Possibly, 
the spatial separation of HDAC1 and HDAC2 manifests in a later embryonic stage of 
chicken development. (Murko et al., 2010) 
Furthermore, the limb buds show high Hdac2 expression from E10 to E13. At E11.5 the 
positive labelling expands to the olfactory placodes and the vibrissae anlage; in the 
latter the enzyme is still found at E13. The branchial arches and their derivates, 
respectively, evince the hybridization signal throughout the investigated developmental 
stages. 
The only internal organs being positive for Hdac2 transcripts are the genital tubercle and 
the developing liver, both displaying the expression of the enzyme at stage E11.5. 
(Murko et al., 2010) 
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Histone deacetylase 3 
In the embryonic organism of the chick HDAC3 is first recognizable at HH14 and HH15 in 
the brain vesicles, neural tube and notochord; the signal expands to the head 
mesenchyme at HH18 and keeps its spatial expression pattern in the CNS and head 
region at HH24. The optic vesicles, the limb buds and the branchial arches show a high 
Hdac3 expression rate at HH18; at HH24 the strong positive labelling extends to the 
somites. In the developing internal organs, like liver, lung, and heart, the expression 
signal is detected at stage HH24. 
 
At developmental day E10 in the mouse HDAC3 was located in the brain where the 
protein is restricted to areas of the fore and midbrain. In addition, the enzyme is also 
clearly observable in the otic vesicles at E10. The limb buds and face mesenchyme of the 
mouse embryo displays an only low expression level of Hdac3 at E11.5 and E13. 
Moreover, at E11.5 Hdac3 was expressed in the genital tubercle; the signal intensifies at 
E13, at which a low expression rate of Hdac3 was observed in the embryonic liver as 
well. 
Generally, Hdac3 presents a comparable spatial and temporal expression pattern as 
Hdacs 1 and 2; however, for the enzyme’s anticipation in quite distinct repressive 
complexes, HDAC3 suggests to have different biological capacities than the other class I 
HDACs. (Murko et al., 2010) 
 
Histone deacetylase 8 
During chick development Hdac8 expression is evident in all regions of the developing 
brain, continuing in the neural tube, in the notochord and head mesenchyme at stages 
HH9 to HH16, diminishing towards HH23. Between HH16 and HH23 the enzyme expands 
throughout the organism and becomes also detectable in the optic and otic vesicles and 
nose placodes, the tail and limb buds, the branchial arches; a low degree of expression is 
observable in the developing nephric ducts, lung buds, liver, and heart anlagen. 
 
In the mouse embryo a modest or low signal intensity of Hdac8 is found to be strictly 
confined to the pros- and mesencephalic areas of the vertebrate brain at stages E10 and 
E11.5. At stage E13 a severe decrease of expression was noticed; HDAC8 is almost 
imperceptible. (Murko et al., 2010) 
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Lein et al. (2007) performed in situ hybridization experiments exhibiting a ubiquitous 
signal of Hdac8 expression in the brains of adult mice with highest levels of transcripts in 
parts of the fore and hindbrain (Lein et al., 2007). 
On the contrary, another study communicated the total absence of HDAC8 expression 
throughout the human nervous system enclosing the brain and spinal cord. The 
experimentation revealed an exclusive Hdac8 expression in human cells determined to 
differentiate into smooth muscle. (Waltregny et al., 2004) 
Otherwise, as mentioned in a previous chapter, a global deletion of Hdac8 in mice was 
found to cause skull instability due to a highly specific inadequacy of cranial neural crest 
cells (Haberland et al., 2009). 
The original papers attempting to determine Hdac8 expression sites report that Hdac8 
mRNA was found in various human tissues (Buggy et al., 2000; Hu et al., 2000; Van den 
Wyngaert et al., 2000). 
In short, approaches of explanation for these seemingly conflicting results throughout 
different species remain to be elucidated (Murko et al., 2010). 
 
1.3.3. Class I HDAC expression in the heart 
 
In this chapter I want to summarize the expression profiles of class I HDACs in the heart 
of chicken and mouse embryos. Concerning the hearts of mouse embryos, the whole 
mount in-situ hybridization brought no conclusive results. Although there exist studies in 
mice inquiring cardiac specific class I HDAC knock-outs and their consequences 
(presented in the previous chapter), Murko et al. (2010) found no detectable 
hybridization signals of HDACs 1, 2, 3 and 8 in the embryonic mouse heart which is 
possibly due to species specific technical limitations of the WMISH. 
In chicken hearts Murko et al. (2010) detected low hybridization signals for HDAC1 at 
developmental stage HH25 (~4.5 days) and for HDAC8 between HH16 (~2.1-2.3 days) 
and HH23 (~3.5-4.0 days). A moderate level of Hdac3 expression was observable at 
stage HH24 (~4.0 days); earlier observations of Hdac3 in the embryonic heart revealed a 
low expression rate of the enzyme already present at stage HH18 (~2.7-2.9 days) (Murko 
et al., unpublished data). For HDAC2 no perceptive positive labelling was found in the 
developing heart of the chick (Murko et al., 2010). 
At the time of the first detection of class I HDAC expression in the heart of the chicken 
embryo, the cardiac development has already undergone several crucial processes: By 
now the heart consists of 3 layers, the endocardium, the myocardium, and the 
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epicardium and lies within the pericardial cavity. The looping of the simple heart tube 
has begun previously and is about to be finished at stage HH16, when expression of class 
I HDACs is firstly localized in cardiac tissues. At that time, cells from the secondary heart 
field, derived from splanchnic mesoderm, have started to become incorporated into the 
myocardium of the ventricular outflow tract. At about HH14 the septa of the heart have 
begun to form. The interatrial septum, dividing the early single atrium in a left and a 
right cavity, is the first visible septum, arising as a ridge at the cranial dorsal wall of the 
single atrium. At HH16 the atrio-ventricular cushions, building the future septum 
between the atria and ventricles, are established of the dorsal and the ventral wall of 
the heart; at about HH24 the cushions meet in the midline and fuse. At the same 
developmental stage the interatrial septum starts to connect with the cushions. The 
division of the originally single ventricle into 2 separated chambers becomes induced at 
HH20-24 when the left and right portions of the primary ventricle bulge; the remaining 
part of the initial wall of the single ventricle is the basis of the interventricular septum. 
This septum originates at the apex of the heart and grows towards the atrio-ventricular 
cushions; with these the septum coalesces at about stage HH29. Right after the bulging 
of the ventricles, at HH24-27, far-ranging trabeculae carnae become generated at the 
ventricular walls and cause these to thicken intensely and to grow muscular. At stage 
HH27 the left and right atria become muscular as well; subsequently, at HH31-37, these 
newly established bands of muscle form so called “muscular arches” which are unique 
for avian atria. Furthermore the cardiac valves (venous, sinu-atrial, and atrio-ventricular 
valves) generally begin to develop at HH24-27. The aortico-pulmonary septum, 
essentially derived from neural crest cells which previously have migrated into the 
developing outflow tract, branches the truncus arteriosus into the aorta and the 
pulmonary artery. This process becomes initiated at about HH27 and is characterized by 
considerable apoptosis and remodelling to enable convenient positioning of the great 
vessels over their corresponding/proper ventricles; consequently, at HH31 the left 
ventricle has gained direct access into the aorta and the right ventricle joins the 
pulmonary artery.  (Bellairs & Osmond, 2005) 
Which role do class I HDACs play in the cardiac development of chicken embryos? Do 
they hold essential functions in the developmental processes of the heart or do they 
only take a marginal part?  
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2. Methods and Material 
2.1. Exposure of the embryonic heart to the histone deacetylase 
inhibitor in ovo 
2.1.1. The choice of the HDAC inhibitor and its carrier 
Trichostatin A (TSA) 
Trichostatin A (TSA) is an organic product of Streptomyces sp. used as a standard HDAC 
inhibitor whose effects are reversible. TSA is a so called pan-HDAC inhibitor targeting 
several classic HDAC isoforms; TSA inhibits the action of all mammalian HDAC members 
of class I and II (HDACs 1-10). (Zhao et al., 2009) 
TSA reversibly blocks the elimination of acetyl moieties from the lysine residues of core 
histones performed by HDACs (Taunton, Hassig, & Schreiber, 1996); consequently, TSA 
escalates the level of histone acetylation (Zhao et al., 2009) and influences the access of 
transcription factors and complexes to genes (Taunton, Hassig, & Schreiber, 1996). This 
elevation of acetylated histones seems to be dose-dependent: Mouse mammary gland 
tumor cells (FM3A) being exposed to 6.7nM TSA showed accumulation of di- and tri-
acetylated histone H4 coinciding with a decrease of non-acetylated H4; an increase of 
tri- and tetra-acetylated H4 and acetylation of alternative core histones were more 
significant in cells treated with TSA concentrations higher than 33nM. Thus, the effect of 
TSA is noteable at low concentrations in the nanomolar range. (Yoshida et al., 1990) 
The inhibition of histone deacetylation by TSA is assumed to cause derepression of 
silenced genes in multicellular eukaryotic organisms (Zhao et al., 2009). In Xenopus 
laevis embryos having been exposed to 30nM TSA were also found to promote histone 
hyperacetylation; no interference with cell division or differentiation being important for 
appropriate morphogenic development was observable (Almouzni et al., 1994). 
Additionally, in pregnant mice having received an injection of 15 µg of TSA (dissolved in 
0.2 ml of Dimethylsulfoxide DMSO) into the abdominal cavity, neither apparent effects 
of toxicity for the mother or for the developing embryo nor teratogenicity were 
recognized; the only detectable consequence of the in vivo TSA administration was the 
disturbed mammalian embryogenesis due to the altered gene transcription caused by 
TSA induced HDAC inhibition (Nervi et al., 2001). Furthermore, two different 
concentrations of TSA were tested on avian limb buds to determine the effects of TSA 
on apoptosis and gene expression in the model system “chicken”. 750 µM or 75µM of 
TSA were loaded on acrylamide beads which were implanted in the developing limbs; 
the beads with the higher loading released about 310.0 to 320.0 nmol TSA per µg beads 
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and the beads soaked in 75µM TSA set 23.5 to 25.0 nmol TSA per µg beads free. It was 
shown that the concentration of 750 µM TSA causes cell death and abberations in limb 
development; the latter are possible secondary effects on gene expression originating 
from apoptosis. Moreover, 12 hours after TSA application on the limb buds apoptosis 
was more pronounced than after 24 hours. Lower concentrations of 75µM TSA did not 
result in cell death, hence, the detected alterations in embryonic development establish 
unassociated to apoptosis. (Zhao et al., 2009) Besides apoptosis, in cancer cells (Chiba et 
al., 2004; Hoshikawa et al., 1994; Yoshida et al., 1990) as well as in rat fibroblast cells 
(Yoshida & Beppu, 1988), a disturbed cell cycle and differentiation are consequences of 
the cells’ treatment with TSA. TSA blocks the G1 and/ or G2/M phases of the cell cycle; 
consequently, the cell growth is inhibited. (Chiba et al., 2004; Hoshikawa et al., 1994; 
Yoshida & Beppu, 1988) Chiba et al. (2004) suggest that the suppression of the growth 
phases depends on TSA concentration and on the point of time it is applied to the cells 
(Chiba et al., 2004). 
In summary, Trichostatin A is a potent HDAC inhibitor which in general is well tolerated 
in vivo and  whose efficacy is mostly dose-dependent. Its good in vivo compatibility is 
attributed to the inhibitor’s incomplete prevention of HDAC activity (in comparison to a 
genetic deletion which results in a total lack of an HDAC) and its only temporary effects. 
In addition, TSA is considered to inhibit only the enzymatic activity without interfering 
with the repressive complex. (Haberland et al., 2008) 
 
Dimethylsulfoxide (DMSO) 
Dimethylsulfoxide (DMSO) is a low-molecular weight compound used as a main organic 
(co-)solvent which increases the solubility of substances to perform experiments 
involving the necessity of cell permeation (Da Violante et al., 2002). DMSO facilitates the 
transport of several substrates across cell membranes (Penninckx et al., 1983); hence, 
DMSO is taken as a vehicle for TSA (Nervi et al., 2001). DMSO is soluble in organic and in 
aqueous media, therefore, it finds use in solubilizing insufficiently soluble compounds. 
For being a carrier substance, DMSO is also used as a solvent for poorly water-soluble 
drugs which need to be absorbed by the skin (e. g. insulin and sulfadiazine). (Da Violante 
et al., 2002) A further characteristic of DMSO is its protection of cell membranes against 
the effects of freezing (Penninckx et al., 1983); accordingly, the solvent is a valuable 
cryoprotectant (Da Violante et al., 2002; Penninckx et al., 1983). Besides these beneficial 
qualities, DMSO has some detrimental toxic effects; the solvent is described to affect the 
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cell membrane and the cell metabolism causing severe damaging of the cell inducing 
apoptosis. (Da Violante et al., 2002) 
Penninckx and colleagues (1983) performed experiments aiming to determine the 
consequences of various DMSO concentrations on dog kidney tissue under different 
conditions. They reported that DMSO concentrations exceeding 10% induced 
disturbance of the membrane integrity and the metabolism of the cell. Morphologically 
the toxicity of DMSO levels higher than 10% resulted in autolytic lesions such as 
degeneration of the cell nucleus, vacuolization of the renal epithelial tissue, and 
separation of the basement membrane (lying under the epithelium) of the kidney; these 
effects were observed at room temperature after 60 minutes of DMSO incubation. If the 
temperature is escalated to 37°C and/ or the exposure time is extended to 120 minutes, 
the cell/ tissue damage becomes more severe. (Penninckx et al., 1983) Concerning the 
temperature Malinin et al. (1967) witnessed the same result in HeLa cells (human 
epitheloid cervical carcinoma cell line): The degree of cell viability decreases with rising 
temperature while maintaining the concentration of DMSO unchanged. (Malinin et al., 
1967)  
Da Violante et al. (2002) also tested the effects of different concentrations of DMSO on 
cell monolayers of the human colon tumor cell line Caco2 clone TC7 (Caco2/ TC7) at 
37°C; the cells were exposed to DMSO for 120 minutes. Up to a concentration of 10% 
DMSO the viability of the cells remained unchanged; when higher concentrations were 
administered to the cells, a drastic decline of viable cells was observable. At a DMSO 
concentration of 20% the percentage of viable Caco2 cells was reduced from 100% 
(negative control) to 73%. Besides the maintained cell viability, at 10% DMSO no 
manifested cytotoxicity could be examined; in contrast to higher concentrations the 
permeability of the apical membrane and the cell-to-cell tight junctions remained 
unaffected at DMSO 10%. (Da Violante et al., 2002) 
Previous studies demonstrated that the cell type is a further crucial factor for the cells’ 
viability. Branch and colleagues (1994) performed experiments with human bone 
marrow hematopoietic progenitor cells to investigate the suggested toxicity of DMSO to 
these types of cells. They found out that particularly colony-forming units 
granulocyte/macrophage (CFU-GM) remain undisturbed after exposure to 8.5% DMSO 
for 120 minutes, whereas the viability of some mononuclear cells became diminished 
under the same conditions. (Branch et al., 1994) Malinin et al. (1967) showed that HeLa 
cells display alterations after being exposed to DMSO concentrations higher than 5-10%; 
the changes examined were independent of the length of exposure (Malinin et al., 
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1967). Watanabe et al. (2000) reported that a concentration of 5% DMSO did not result 
in damage of the cell membranes of isolated rat intestinal tissue in permeation studies 
using an Ussing chamber (scientific equipment used to determine ion transport in 
tissues); the experiments took up to 100 minutes (Watanabe et al., 2000). Nervi et al. 
(2001), already mentioned in the previous chapter for using pregnant mice for their 
experiments with TSA, injected 0.2 ml of DMSO into the mice’ abdominal cavity to use 
them as controls for the TSA treated mice; they could not observe any apparent 
alterations in the embryo or the mother (Nervi et al., 2001). 
Taking these various factors influencing toxicity (concentration, exposure time, 
temperature, and cell type) into account, Dimethylsulfoxide is a sufficient carrier 
substance in multiple experimentations. 
 
2.1.2. Preparation of TSA for administration to the embryonic hearts 
TSA was applied to heparin-acrylic beads (0.57 mg heparin/ml packed acrylamide gel; 
Sigma, H5263). All centrifugation steps were carried out in a mini-centrifuge (Sprout) at 
maximum speed (6000 rpm).  The used Locke-solution (isotonic electrolyte-containing 
solution used to keep living samples for experimental purposes) was autoclaved. 
500 µl of the beads in saline suspension were centrifuged for a few seconds and the 
supernatant was discarded. 500 µl of Locke-solution were added to the beads, and after 
vortexing for about 30 sec, the beads were centrifuged again. This step was repeated 
twice. Before the last centrifugation step, the beads were divided equally into two 500-
µl-Eppendorf tubes; to one half of the beads TSA was added and the other half was 
soaked in DMSO for control embryos. After centrifuging, the supernatant was removed, 
so that 100 µl of the beads in Locke-solution remained in each tube. Subsequently the 
beads were incubated with 5 µl of TSA stock solution (1 mg/ml) or 5 µl DMSO 1%; the 
final TSA concentration was 165.36 µM and the concentration of DMSO was 0.05%. Both 
tubes were vortexed and kept at 4°C overnight (o. n.) in a horizontal position. On the 
next day the tubes were centrifuged and the supernatant discarded. The following 
washing step was repeated twice: 400 µl of Locke-solution were added to the beads; 
after vortexing and centrifuging, the supernatant was removed. Again 400 µl of Locke-
solution were transferred to the beads; the tubes were vortexed and kept at 4°C for 1 h. 
The subsequent wash of the beads was accomplished by vortexing and centrifuging the 
tubes and removing the supernatant. This washing step was repeated using 200 µl of 
Locke-solution; the remaining supernatant covered the beads to avoid dehydration. At 
last, the tubes were put on ice; the beads were ready for use. (Zhao et al., 2009) 
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Besides the implantation of beads, 2 different concentrations of TSA were tested for 
direct injection into the pericardial cavity of the embryonic heart. The desired TSA or 
DMSO concentrations were achieved by dilution of TSA stock solution (1 mg/ml) or pure 
DMSO with Locke-solution; the final concentrations were as follows: 165.36 µM TSA and 
0.05% DMSO; 50 µM TSA and 0.015% DMSO. TSA and DMSO solutions were labeled with 
vital dye fast green (Sigma-Aldrich) to be able to locate the exact injection site, i.e. the 
pericardial cavity. Fast green was prepared as a 1% solution (the dye was dissolved in 
Aqua dest.); the dye solution was used 1:10 to the final volume of TSA or DMSO 
solutions. 
 
Locke-solution, pH 7.4 
8.5 g NaCl 
0.42 g KCl 
0.24 g CaCl2 
1000 ml Aqua dest. 
 
DMSO 1% 
Pure DMSO 
Locke-solution 
 
TSA stock solution (1 mg/ml) 
1 mg TSA 
1 ml DMSO 1% 
 
2.1.3. Exposure of the embryonic hearts to TSA in ovo 
Fertilized chicken eggs (White Leghorn, Gallus gallus domesticus) were acquired from a 
breeder in Gloggnitz, Lower Austria (Schropper). The eggs were incubated at a 
temperature of 37°C and relative humidity of 60% for 4 days up to Hamburger-Hamilton 
(HH) stages 23-24. The determination of the developmental stages of the chicken 
embryos accords to Hamburger, V. and Hamilton, H. L. (1951). The embryo exposure to 
TSA in ovo was performed with sterile surgical instruments. 
Prior to aspirating 1.5-2.0 ml of egg white through the air sac, the egg shell atop of the 
air sac was incised with a fine saw to facilitate the access with the syringe. The eggs 
were windowed using a fine saw and forceps. Afterwards the embryos were hoisted by 
compensating the reduction of egg white with Locke-solution (used as an egg white 
substitute) to support the following operation steps taking place under a stereo 
microscope (Leica IC80 HD): Within the operation field the vitelline membrane, the inner 
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and outer membrane of the amniotic sac, the ectoderm and the pericardium were cut 
open with a tungsten needle. For better differentiation of the membranes Nile blue 
sulfate (0.1 mg/ml PO4 buffer) was used to stain them. The beads having been soaked 
with TSA or DMSO (for the control embryos) were absorbed up a pulled glass needle 
attached to a rubber tube and positioned near the embryo. With a blunt needle 1-4 
beads were pushed through the slit in the pericardium (which should not be to long so 
that the beads stay at the desired position) and remain in the pericardial cavity of the 
embryo. 
As mentioned in the previous chapter, 2 different concentrations of TSA and DMSO were 
tested by direct injection. Like the beads, the injection solutions were soaked up a fine 
pulled glass needle attached to a rubber tube and directly injected into the pericardial 
cavity of the embryonic heart. 
After the implantation of the beads or the injections, the embryo was once again 
lowered by aspiration of the egg white with a syringe. The operation window and incised 
air sac were sealed with medical tape. Subsequently, the eggs containing embryos with 
implanted beads were reincubated for 36-48 h; the embryos having been injected were 
reincubated for 8-24 h. 
 
2.1.4. Removal and fixation of the treated embryonic hearts 
 
The operation window of the reincubated eggs was reopened, the developmental stages 
of the embryos were determined in accordance to Hamburger and Hamilton and 
deviations were documented. Next, the embryo was cut out of the egg, put into a Petri 
dish filled with Locke-solution and freed from the enclosing membranes. The embryonic 
heart was removed by using appropriate surgical instruments and again aberrations 
were noted. Immediately the heart was photographed under a microscope (Leica MZ16 
F) equipped with a digital camera (Nikon DN100). Next, the heart was fixed in 4% PFA for 
24 h; subsequently, PFA was replaced by 1x PBS. 
 
1x PBS, pH 7.4 
150 mM NaCl 
16.69 mM Na2HPO4 
1.66 mM NaH2PO4 
Aqua dest. 
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PFA 4%, pH 7.4 
1x PBS 
4% PFA 
 
2.2. Histological and morphometric analysis of the treated embryonic 
hearts 
2.2.1. Paraffin embedding and sectioning 
After fixation with PFA 4%, the hearts were washed 3 times for 30 min with 1x PBS. The 
specimens were dehydrated by incubation in a graded ethanol series beginning with the 
lowest and ending with the highest concentration; ethanol concentrations were as 
follows: 60% - 70% - 80% - 90% - 95% - 100%. In each of the different concentrations the 
samples were kept for 30 min; 100% ethanol was administered twice to the hearts, each 
time for 30 min. Subsequently, methyl benzoate was added to the hearts for 4 times; 
each time the hearts had to sink to the bottom of the vial before the methyl benzoate 
was changed. Afterwards the methyl benzoate was replaced by benzene for 2.5 min. 
After repeating the benzene step 3 times, a mixture of benzene and soft paraffin was 
applied to the samples for 5 min. All these steps were carried out with tightly capped 
vials to prevent evaporation of the alcohol; the following procedures were performed 
with uncapped vials. Next, the benzene-soft paraffin mixture was removed and pure soft 
paraffin was added to the hearts; the vials were incubated for 30 min at 40°C. 
Afterwards, 4 paraplast changes were accomplished: The first change took place after 
incubation for 30 min, 1-2 h later the next paraplast change was performed and the last 
2 incubations with paraplast took 3-4 h each. After each exchange the vials were put 
into the incubator at 60°C. The incubation of the samples in 70% ethanol, the methyl 
benzoate step, and the last 2 paraplast changes could be accomplished o. n.. The 
described procedures were applied to the hearts with implanted beads. The numerous 
specimens obtained by injection experiments were embedded by an automatic 
embedding machine (medite Tissue Processor TPC 15). The first steps of paraffin 
embedding (till the incubation of the hearts in 70% ethanol) were carried out manually; 
afterwards the embedding machine was programmed as follows: 
 
Step Incubation in … Temperature Time (h:min) 
01 Ethanol 70% 30°C 1:00 
02 Ethanol 70% 30°C 1:30 
03 Ethanol 80% 30°C 1:00 
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04 Ethanol 80% 30°C 1:30 
05 Ethanol 96% 30°C 1:00 
06 Ethanol 96% 30°C 1:30 
07 Ethanol 96% 30°C 2:00 
08 Xylene 30°C 0:30 
09 Xylene 30°C 1:00 
10 Xylene 30°C 1:30 
11 Paraplast (melting point at 60°C) 55°C 1:30 
12 Paraplast (melting point at 60°C) 55°C 1:30 
13 Paraplast (melting point at 60°C) 56°C 2:00 
14 Paraplast (melting point at 60°C) 56°C 2:30 
 
The ensuing embedding of the hearts took place at an embedding station: An 
embedding boat was half filled with paraplast and the heart was properly positioned for 
sectioning with pre-heated forceps. The embedding boat was shortly put on the freezing 
plate of the embedding station; thus, the paraplast began to solidify at the bottom of 
the boat and the position of the sample was fixed.  An embedding cassette without lid 
was placed above the sample in the embedding boat which then was filled up with 
paraplast. Subsequently, the embedding boat was deposited on the freezing plate for 
about 1 h till the paraplast had solidified completely. 
Afterwards the solid paraplast block with the embedded sample was trimmed and 
sectioned at a thickness of 4 µm using a microtom (Thermo Shandon Finesse); the hearts 
were sectioned serially. The longitudinal sections were mounted onto HistoBond 
adhesive slides (Marienfeld) and incubated o. n. at 42°C to bind the sections to the 
slides. 
 
2.2.2. Mayer’s hematoxylin and eosin staining 
The HistoBond adhesive slides were sorted into a cuvette. Before the staining procedure 
began, the sections were deparaffinized and rehydrated. For deparaffinization the slides 
were put in xylene 3 times, each time for 7 min. The following rehydration occurred by 
incubation of the slides in a graded ethanol series beginning with the highest and ending 
with the lowest concentration; ethanol concentrations were as follows: 100% - 95% - 
90% - 80% - 70% - 60%. In each of the different concentrations the samples were kept 
for 3 min; 100% ethanol was administered twice to the slides (1 brief wash to remove 
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the xylene, 1 x 3 min). After rehydration the slides were rinsed twice in distilled water. 
The staining step followed: Mayer’s Hematoxylin (AppliChem, A4840) was filtered and 
applied to the slides for 2 min. Immediately, the slides were rinsed 3 times in distilled 
water. The staining was examined under the microscope; if not only the nuclei were 
stained but also the cytoplasm, a differentiation step followed. The slides were 
differentiated in 70% hydrochloric acid-ethanol for 6 sec. Afterwards the slides were 
immediately rinsed twice in distilled water. If necessary the differentiation step was 
repeated; incubation time was adapted. Subsequently the slides were washed under 
running tab water for 10 min until the pink stained cell nuclei of the heart sections 
changed to blue. The slides were rinsed twice with distilled water. Next, the slides were 
counterstained in filtered 0.1% eosin solution for 2 min (staining the cytoplasm pink) 
and afterwards rinsed twice with distilled water. Subsequently, the sections were again 
dehydrated: in 95% ethanol the slides were washed briefly; 2 changes of 100% ethanol 
followed, 30 sec each. Then the slides were cleared in 4 changes of xylene (1 brief wash, 
3 x 3 min). At last the sections were mounted with Eukitt Mounting Medium (xylene 
based synthetic resin). 
 
Eosin stock solution 1% 
1 g eosin 
Aqua dest. to a final volume of 100 ml 
 
Eosin working solution 0.1% 
10 ml eosin stock solution 1% 
90 ml Aqua dest. to a final volume of 100 ml 
3 drops glacial acetic acid (concentrated, H2O-free) 
 
2.2.3. Morphometric analysis 
After approximately 2 days the mounting medium had dried and the histological stained 
sections of the embryonic chicken hearts could be examined and photographed using a 
Nikon Eclipse 800 epifluorescence microscope equipped with a digital camera. Next, the 
images were measured using ImageJ 1.41 bundled with Java 1.6.0_10; the area of the 
left and right ventricle and of the atria were the evaluated features. The subsequent 
analysis comprised the determination of the areal sum of both ventricles and of the 
areal proportion of atria to ventricles and of left ventricle to right ventricle by using 
Microsoft Office Exel 2007. 
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2.3. Analysis of proliferation and apoptosis in the treated embryonic 
hearts 
2.3.1. Bromodeoxyuridine (BrdU) cell proliferation assay 
BrdU is a synthetic nucleoside substituting thymidine during DNA replication, thus, it 
becomes incorporated into the newly synthesized DNA of dividing cells. The detection is 
achieved with a BrdU-specific antibody. 
Before being able to perform the proliferation assay, the embryos had to be treated 
with bromodeoxyuridine (BrdU) in ovo: 1 h before the embryonic hearts were to be 
removed, the eggs were reopened and 200 µl of 1x PBS containing 10 mM BrdU(Sigma) 
were dripped on each embryo. The reopened operation window was sealed with 
medical tape and the eggs were reincubated for 1 h. After the following removal and 
fixation of the hearts, the samples were embedded in paraffin and sectioned as 
described above. On each slide 2 sections were mounted; one section was derived from 
a BrdU treated heart and the other one was acquired from an untreated specimen (for 
the negative control). Both sections underwent the same procedures as described 
below. 
The sections were additionally dried at 58°C for 60 min, deparaffinized and rehydrated. 
For deparaffinization the slides were put in xylene 4 times (3 x 30 min, 1 x o. n). On the 
next day rehydration occurred by incubating the slides in a graded ethanol series 
beginning with the highest and ending with the lowest concentration; ethanol 
concentrations were as follows: 100% (twice)- 95% - 90% - 80% - 70% ethanol mixed 
with 0.25% NH3 - 60%. In each of the different concentrations the samples were kept for 
5 min; in the solution of NH3-ethanol the slides were incubated for 45 min. After 
rehydration the slides were rinsed in distilled water and, subsequently, in 1x TBS. 
Afterwards the sections were pre-treated with 1x TBS containing 1% NaBH4 for 40 min, 
then washed in 1x TBS (one brief wash, 1 x 15 min) and rinsed with distilled water. After 
the washing step another pre-treatment, DNA denaturation of the cells of the sectioned 
heart tissue, followed: The slides were incubated in 2N HCl at 37°C (water bath) for 60 
min. Next, the acid was neutralized by washing the slides 3 times in 0.1M borate buffer 
(one brief wash, 2 x 5 min). After 4 additional changes of 1x PBS (one brief wash, 3 x 5 
min) the slides were pre-incubated in blocking solution at room temperature (RT) in a 
wet chamber for 45 min. Subsequently, the slides were incubated with the first antibody 
α-BrdU (mouse) (IgG; Roche) diluted 1:20 in blocking solution at 4°C in a wet chamber o. 
n. On the next day the slides were washed 4 times with 1x PBST (each wash took 30 min) 
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before the secondary Alexa 488-labeled α-mouse antibody (goat) (Southern 
Biotechnology) diluted 1:1000 in blocking solution was applied to the slides for 60 min at 
RT in a wet chamber. After 3 washes with 1x PBST (one short wash, 2 x 5 min), the nuclei 
in the heart tissue were counterstained in a DAPI containing solution (0.1 µg DAPI/ml 
PBST) for 5 min. Additional 3 washes with 1x PBST were followed by mounting of the 
slides with Citifluor (a non-fluorescent immersion oil containing an antifading agent; 
Christine Gröpl). The slides were kept at 4°C until examination and documentation of 
the fluorescently labeled cell nuclei of the embryonic chicken hearts via fluorescence 
microscopy (Nikon Eclipse 800 epifluorescence microscope). 
 
1x TBS, pH 7.4 
20 mM Tris/HCl, pH 7.4 
150 mM NaCl 
Aqua dest. 
 
Borate buffer, pH 8.5 
0.1 M borax (sodium tetraborate)/H3BO3, pH 8.5 
Aqua dest. 
 
1x PBST 
1x PBS, pH 7.4 
0.05% Tween 20 
 
Blocking solution, pH 7.4 
1x PBST 
1% BSA 
 
2.3.2. Terminal transferase dUTP nick end labeling (TUNEL) cell apoptosis 
assay 
TUNEL is a method which enables the detection of DNA fragments caused by apoptosis. 
The enzyme terminal transferase identifies the presence of nicks in the DNA and 
catalyzes the addition of dUTPs. The dUTPs are labeled with a marker which can be 
detected by an antibody specific for that marker. 
For the TUNEL assay the embryos did not have to be pre-treated with a chemical 
substance; instead the 3 sections which have been mounted on each slide (the sample, a 
positive and a negative control) had to be treated differently. 
The first steps of the TUNEL assay (i. e. the additional drying, the deparaffinization, the 
rehydration, the washing, and the pre-treatment with 1x TBS containing 1% NaBH4) 
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were the same as for the BrdU proliferation assay. After the pre-treatment of the slides 
with 1x TBS containing 1% NaBH4, the slides were washed in 1x TBS (one brief wash, 2 x 
5 min). The next step was the DNase digest of the positive controls with a DNase 
containing buffer at 37°C (incubator) in a wet chamber for 10 min. During that digest the 
negative controls and the samples were incubated with 1x TBS, also in a wet chamber, 
to prevent the sections from drying. After a rinse and following 2 washes (5 min each) 
with 1x PBST, the reaction mix containing terminal transferase and a dNTP nucleotide 
mix including digoxigenin-lableled dUTP was applied to the samples and the positive 
controls for 30 min at 37°C (incubator) in a wet chamber; each section was incubated in 
5 µl of the reaction mix. The negative controls were incubated with a reaction mix 
excluding the terminal transferase; the amount of the enzyme was replaced by DEPC-
H2O. The incubation of the negative controls took place under the same conditions as 
the incubation of the samples and positive controls. After 4 changes of 1x PBST (one 
brief wash, 3 x 5 min) the slides were pre-incubated in blocking solution for 30 min at RT 
in a wet chamber. Subsequently, the slides were incubated with a FITC-labeled α-Dig 
antibody (sheep) (Roche) diluted 1:100 in blocking solution at 4°C in a wet chamber o. n. 
On the next day the slides were washed 3 times with 1x PBST (1 x 15 min, 2 x 30 min).  
Afterwards the nuclei in the heart tissue were counterstained in a DAPI containing 
solution (0.1 µg DAPI/ml PBST) for 5 min. Additional 3 washes with 1x PBST (one brief 
wash, 2 x 5 min) were followed by mounting of the slides with Citifluor (Christine Gröpl). 
As the BrdU treated sections, the slides were kept at 4°C until the fluorescently labeled 
cell nuclei of the embryonic chicken hearts were examined and documented using a 
fluorescence microscope (Nikon Eclipse 800 epifluorescence microscope) equipped with 
a digital camera. 
 
DNase buffer for DNase digest 
50 mM Tris/HCl, pH 7.5 
0.1% BSA 
Aqua dest. 
 
DNase containing solution 
x ml DNase buffer 
3 U DNase/ml buffer (DNase stock: 10 U/µl; Sigma) 
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Reaction mix containing terminal transferase 
20% 5x buffer (Promega) 
10% nucleotide mix 
0.25 U terminal transferase/µl final volume (terminal transferase stock: 30 U/µl; 
Promega) 
x µl DEPC-H2O to the desired final volume 
 
Nucleotide mix (all dNTPs purchased from Roche) 
5 µl 2.5 mM dATP 
5 µl 2.5 mM dCTP 
5 µl 2.5 mM dGTP 
3.4 µl 2.5 mM dTTP 
4 µl 1 mM dUTP-Dig 
27.6 µl dH2O to a final volume of 50 µl 
 
2.4. Analysis of the acetylation level of the treated embryonic hearts 
2.4.1. Preparation of the hearts for histone isolation 
After exposure of the embryonic hearts to TSA or DMSO, the eggs were reincubated for 
6 h or 24 h, respectively. Following the removal of the embryos, they were immediately 
deposited in 1x PBS containing 10 mM sodium butyrate to maintain the acetylation level 
of the core histones in the nuclei of the cardiac tissue. Surrounded by the sodium 
butyrate solution, the hearts were extracted and collected in 500-µl-Eppendorf tubes 
also filled with sodium butyrate solution. The subsequent brief centrifugation step was 
carried out in a mini-centrifuge (Sprout) at maximum speed (6000 rpm). After discarding 
the supernatant, the hearts were shock frozen in liquid nitrogen and either stored at -
80°C or instantly used for histone isolation. 
 
2.4.2. Histone isolation 
100 µl ice-cold histone lysis buffer were added to the frozen hearts which subsequently 
were homogenized with a pestle. Then a further 900 µl of ice-cold lysis buffer were 
added to the homogenisate. After vortexing, the samples were centrifuged at 12 500 
rpm for 5 min at 4°C and the supernatant was discarded. A wash with the lysis buffer 
followed: The cell pellet was resuspended in 1 ml of the ice-cold buffer by vortexing 
vigorously and again centrifuged at 12 500 rpm for 5 min at 4°C; afterwards the 
supernatant was removed. This washing step was repeated 3 times and followed by an 
additional wash with 1 ml histone wash buffer. Subsequently, the cell pellet was 
resuspended in 100 µl ice-cold H2O, ultrapure (Sigma) and concentrated H2SO4 was 
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added 1:100 to a final concentration of 0.4 N; by the acidic milieu, the histones were 
dissolved in the liquid. After vortexing, the samples were incubated on ice for at least 2 
h. Next, the samples were centrifuged at 14 000 rpm for 10 min at 4°C and 10x volumes 
acetone (for histone precipitation) were added to the supernatant, which then 
contained the histones. After an additional vortexing step, the tubes were incubated at -
20°C o. n. On the next day, the samples were again spun down at 14 000 rpm for 15 min 
at 4°C and the supernatant was removed by decanting. Then, the histone pellet was 
washed twice with acetone: The pellet was resuspended in 1 ml acetone by vortexing 
intensely and centrifuged at 14 000 rpm for 5 min at 4°C; afterwards the supernatant 
was decanted or removed with a pipette (if the pellet did not adhere to the tube). After 
air drying, the histone pellet was resuspended in 10 mM Tris (pH 6.5); that protein 
extract was either stored at -80°C or immediately used for further experiments. 
 
Histone lysis buffer, pH 6.5 
10 mM Tris 
50 mM sodium bisulfite 
1% Triton X-100 
10 mM MgCl2 
10 mM sodium butyrate 
8.6% sucrose 
 
Histone wash buffer, pH 7.4 
10 mM Tris 
13 mM Na3EDTA 
 
2.4.3. Bradford assay 
Bradford reagent (Bio-Rad) was diluted 1:5 with dH2O and filtered through a 45 µm 
filter. 1 µl of histone extract was added to 1 ml of diluted Bradford reagent. The 
absorbance of the samples was measured at a wave length of 595 nm with a Bio-Rad 
SmartSpecTM Plus Spectrophotometer and the protein concentration was determined 
according to a standard curve. The determination of the concentrations of the different 
protein samples was needed to be able to load equal amounts of proteins on the gels for 
SDS-PAGE. 
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2.4.4. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
The extracted histones were separated on 16% polyacrylamide gels which were overlaid 
with 5% stacking gels. The gels had a thickness of 0.75 mm using the Bio-Rad Mini gel 
system. The amounts of the different components for 2 mini gels were as follows: 
 
Separating gel: 16% Stacking gel: 5% 
Solution A 
Solution B 
Aqua dest. 
10% APS 
TEMED 
4.8 ml 
2.25 ml 
1.95 ml 
90 µl 
7.5 µl 
Solution A 
Solution C 
Aqua dest. 
10% APS 
TEMED 
1 ml 
1.5 ml 
3.5 ml 
60 µl 
5 µl 
Total volume 9 ml Total volume 6 ml 
 
Solution A: 30% acrylamide, 0.8% bisacrylamide 
Solution B: 1.5 M Tris/HCl, pH 8.8; 0.4% SDS 
Solution C: 0.5 M Tris/HCl, pH 6.8; 0.4% SDS 
 
The components of the separating gel were combined and poured into the previously 
cleaned gel unit and overlaid with a small quantity of isopropanol to ensure the 
straightening of the top level of the gel. After the polymerization of the separating gel 
which took 15 min, the isopropanol was removed completely and the components of 
the stacking gel, having already been mixed, were poured onto the separating gel. 
Immediately, the comb was inserted and the stacking gel was allowed to polymerize for 
at least 15 min. Afterwards, the comb was removed and the slots were rinsed with Aqua 
dest. After putting the gel into the buffer chamber filled with 1x running buffer, the 
protein samples were prepared as follows: Equal amounts of proteins from the different 
histone samples were mixed 1:1 with 2x Laemmli buffer containing 5% β-
mercaptoethanol (reducing; Bio-Rad) and denatured at 95°C for 5 min. After storing the 
samples on ice for a few min, the denatured histone samples were loaded on the gel. 
The gel was run at 80 V until reaching the separating gel and then shifted to a constant 
voltage of 90 V until the Bromphenol Blue reached the bottom of the gel. 5 µl of 
Kaleidoscope Prestained Protein Standard (Bio-Rad) served as size marker. 
One of the 2 gels was used for Western blot analysis and one was stained with 
Coomassie Blue. 
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1x running buffer, pH 8.3 
25 mM Tris 
192 mM glycine 
0.1% (w/v) SDS 
 
Protein samples 
x µl histone extract 
y µl 10 mM Tris, pH 6.5 
(x+y) µl 2x Laemmli buffer 
 
2x Laemmli buffer 
62.5 mM Tris/HCl, pH 6.8 
25% glycerol 
2% SDS 
0.01% Bromphenol Blue 
5% β-mercaptoethanol 
 
2.4.5. Coomassie staining and gel drying 
After running the gels, one of them was stained with Imperial protein staining solution 
(Pierce) for 1 h and subsequently washed with distilled water o. n. On the next day the 
background staining was reduced and the bands were clearly visible. Next, the gel and 2 
sheets of cellophane paper were equilibrated in gel drying solution (Invitrogen); the gel 
was only incubated for 30-60 sec, because the drying solution diminishes the staining 
and makes the gel brittle. After arranging the gel between the cellophane sheets and 
fixing that sandwich into the gel drying equipment, the gel was dried for at least 8 h. 
Then, the gel was cut out of the equipment with a scalpel. 
 
2.4.6. Western blot analysis 
Semi dry blotting 
The transfer of the separated proteins from the SDS-gel to nitrocellulose membrane 
(Bio-Rad Trans-Blot®) was performed in a semi-dry blotting unit (Bio-Rad Trans-Blot® SD). 
Before the assembly of the blotting sandwich, the anode and cathode platform of the 
blotting unit were moistened with 1x blotting buffer. Next, the blot was prepared as 
follows: First 1 sheet of extra thick filter paper was applied to the blotting unit, followed 
by the nitrocellulose membrane, the gel, and finally 1 more sheet of filter paper; all 
components of the blotting sandwich were soaked in 1x blotting buffer before the 
assembly. To exclude air bubbles within the blotting sandwich, a falcon tube was rolled 
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over it. The blot was covered with the cathode platform and subsequently with the lid of 
the blotting unit. The protein transfer was performed for 30 min at 20 V. To check the 
efficiency of the blotting, the membrane was stained with Ponceau S for 5-10 min. 
Subsequently, the transferred proteins and the used size marker were visualized by 
destaining with distilled water. The bands of the size marker were traced with a ballpen. 
 
1x blotting buffer, pH 8.3 
25 mM Tris 
192 mM glycine 
0.1% (w/v) SDS 
10-20% methanol 
 
Ponceau S, pH 8.3 
0.2% Ponceau S 
3% trichloroacetic acid 
3% sulfosalicylic acid 
 
Detection 
For visualization of the expected proteins on immunoblots, an enhanced 
chemiluminescence (ECL) assay was used. ECL is based on the use of luminol and an 
oxidizing reagent and depends on enzyme-catalyzed production of light: Horse radish 
peroxidase (HRP) conjugated to the secondary antibody catalyzes the oxidation of 
luminol in the presence of hydrogen peroxide (H2O2) being contained in the oxidizing 
reagent; thus, light emits and the desired proteins can be detected. 
The membrane was pre-incubated in blocking solution at room temperature (RT) in a 
wet chamber for 30 min. After removing the blocking solution, the membrane was 
incubated with the first antibody α-AcH3 diluted 1:5000 in blocking solution at 4°C in a 
wet chamber with gentle agitation o. n.. On the next day the membrane was washed 
with 1x PBST (3 x 10 min) before the secondary HRP-labeled α-rabbit antibody diluted 
1:10 000 in 1x PBST was applied to the membrane for 45-60 min at RT in a wet chamber 
with gentle agitation. The secondary antibody must not be diluted in blocking solution, 
because HRP tends to react with NaN3; hence, the HRP-dependent catalyzation acquired 
for the light emission would be prevented. After another wash with 1x PBST (3 x 10 min), 
the membrane was finally treated with a chemoluminescent solution to visualize the 
HRP conjugates. Therefore luminol and oxidizing reagent (Perkin Elmer) were freshly 
mixed 1:1 and directly applied to the membrane which was then packed in saran wrap 
and fixed into an exposure cassette with the protein side up. X-ray films (Kodak) were 
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exposed to the membrane for 2-15 min, depending on the intensity of the signal and 
background. 
After an additional washing step with 1x PBST (one brief wash, 2 x 10 min), a second and 
third immunodetection with different primary antibodies (α-AcH4, α-C-terminal H3) 
were performed under the same conditions. The secondary antibody and its dilution 
remained the same as described above. 
All primary antibodies as well as the secondary antibody were kindly provided by Mag. 
Dr. Christina Murko. 
  Manufacturer Dilution Host species 
Primary 
antibodies 
α-AcH3 Millipore 1:5000 rabbit 
α-AcH4 Millipore 1:5000 rabbit 
α-C-terminal 
H3 
Abcam 1:20 000 rabbit 
Secondary 
antibody 
α-rabbit-HRP Amersham 1:10 000  
 
Blocking solution 
1x PBS 
1% PVP 
1% non-fat dry milk 
0.1% Tween 20 
0.01% NaN3 
 
1x PBST 
1x PBS, pH 7.4 
0.1% Tween 20 
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3. Results 
3.1. Histological and morphometric analysis of the treated embryonic 
hearts 
To be able to analyze the effects caused by down-regulation of class I HDACs in the 
developing hearts of chicken embryos, the hearts were exposed to the histone 
deacetylase inhibitor TSA during stage HH 23-24 of embryogenesis. The administration 
of TSA to the chicken hearts was accomplished by implantation of TSA soaked beads or 
direct injection of the inhibitor; 2 different concentrations of TSA were tested. After 
reincubation of the embryos, the hearts were removed and photographed. For 
histological analysis the hearts were fixed, embedded, sectioned and stained; the cell 
nuclei of the heart tissue were dyed blue and the cytoplasm was counterstained pink. 
These histological stained sections of the embryonic chicken hearts were examined and 
photographed. During the microscopic observation of the sections, the most prominent 
phenotypes being detected were aberrant areal proportions of atria to ventricles and of 
left ventricle to right ventricle. Therefore the areas of the left and right ventricle and of 
the atria were the subsequently measured and evaluated features. Additionally, the 
areas of the whole hearts were measured to be able to compare the sizes of TSA treated 
hearts and control hearts. 
Analyzing the data of the areal measurements of the whole hearts, a hypertrophy of the 
TSA treated cardiac tissue was evident (Graph 1). Graph 1 shows the combined mean 
values of the measurements of all examined cardiac tissue, including the hearts after 
implantation of beads and the hearts after direct injection into the pericardial cavity. 
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Graph 1: Mean values of the areal measurements of the whole hearts. The analysis included 7 
TSA treated hearts (the values of these consist of the measured values of 3 hearts after 
implantation of beads and of 4 hearts after injection), 4 DMSO treated hearts and 2 untreated 
hearts. Values are given in pixels. 
 
Interestingly, differences in phenotypic effects were observed after either implantation 
of beads soaked in the inhibitor or direct injection of TSA into the pericardial cavity. 
The TSA treated hearts obtained after implantation of beads displayed an increase in the 
size of the ventricles and of the atria; the increase in size of the atria was nearly as high 
as the increase of size of the ventricles (Graph 2). The implantation of beads generates a 
local source of high TSA concentration and consequently exerts a local effect on the 
cardiac tissue depending on the site of implantation; thus, each single heart of the 
implantation series was compared to the mean values of the atrial and ventricular areas 
of the control hearts. As a result, 50% of the phenotypic alterations were an atrial 
hypertrophy and 50% of the arisen phenotypes were a ventricular hypertrophy; one of 
the specimens displayed a severe atrial hypertrophy and, additionally, a slight 
enlargement of the ventricles. The combination of the individual areal mean values of 
these hearts resulted in a similar increase in size of atria and ventricles (as seen in Graph 
2). Consequently, the variable phenotypes of TSA treated hearts after implantation of 
beads caused a balanced increase in size of the atrial and the ventricular area. 
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Graph 2: Mean values of the areal measurements of the whole hearts; the TSA treated hearts 
were exposed to the HDAC inhibitor by implantation of heparin-acrylic beads soaked in TSA. The 
analysis included 3 TSA (165 µM) treated hearts, 4 DMSO (0.05%) treated hearts and 2 untreated 
hearts. Values are given in pixels. 
 
The hearts which were exposed to TSA by direct injection showed a clear increase in 
atrial size and a minimal reduction in the size of the ventricles (Graph 3). In contrast to 
the implantation of beads, injections result in a homogenous distribution of TSA within 
the pericardial cavity as judged by homogenous distribution of the co-injected fast green 
and, thus, seem to generate rather homogeneous phenotypes. Like with the cardiac 
tissue after implantation of beads, each one of the injected hearts was also compared to 
the mean values of the atrial and ventricular areas of the control hearts. Every heart 
displayed an atrial hypertrophy; one specimen was generally smaller than the other 
measured hearts and, consequently, caused the minimally reduced mean ventricular 
area of the TSA treated hearts which is apparent in Graph 3. Concerning the injected 
hearts, the atrial hypertrophy represents a homogeneous phenotype which was even 
reflected in the areal mean values of the atria and the ventricles of the TSA treated 
cardiac tissue (Graph 3). 
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Graph 3: Mean values of the areal measurements of the whole hearts; the TSA treated hearts 
were exposed to the HDAC inhibitor by direct injection of TSA. The analysis included 4 TSA 
treated hearts (3 specimens were treated with 50 µM TSA and 1 heart was treated with 165 µM 
TSA), 4 DMSO (0.05%) treated hearts and 2 untreated hearts. Values are given in pixels. 
 
In total, 57 histological evaluable hearts were observed: 22 hearts were treated with 
TSA, to 28 hearts DMSO was administered and 7 hearts received no treatment. 
The chicken hearts treated with TSA displayed multiple phenotypes. All 5 embryonic 
hearts affected by implantation of acrylic beads loaded with 165 µM of the HDAC 
inhibitor showed deviant areal proportions of atria to ventricles; atrial hypertrophy (Fig. 
1) was detected in 60% of the cardiac tissue and in 40% ventricular hypertrophy (Fig. 2) 
was noted. 4 of these hearts revealed several other alterations: Hypertrophy of the right 
ventricle (Fig. 2) was found in 75% of the hearts, malformations of the ventricular 
septum (missing septum, inappropriate septation) were observed in 50% of the samples, 
disturbances in the formation of the outflow tract (incorrect positioning, hypertrophy) 
were also recognized in 50% and in 25% of the cardiac tissues the sinus venosus was 
formed notably massive. 
The implantation of TSA soaked acrylic beads generated rather heterogeneous 
phenotypes; as mentioned above, the effect of the beads is assumed to be a local one 
and to depend on the implantation site and also on the heartbeat, which is able to 
rearrange the position of the bead. Therefore, the heart area affected by TSA and its 
association to the observed phenotype is difficult to determine. Injections enable a 
better distribution of the HDAC inhibitor within the pericardial cavity and are expected 
to induce more consistent phenotypes. However, the influence of the injected TSA on 
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the hearts is considered less severe, because injections have no repository qualities and 
the effects are believed to wash off more quickly. 
The first series of TSA injections into the pericardial cavity of the embryonic hearts was 
performed with a 165 µM solution of the HDAC inhibitor. As a consequence half of the 
treated embryos died during the 24-hour reincubation time; therefore, 2 different 
concentrations of TSA, 50 µM and again 165 µM, were tested in the next injection 
sequence. This time only 3 of 14 TSA treated embryos died; to all 3 of them the 50 µM 
TSA solution was administered. This lethality is supposed to be due to serious organic 
damages caused during the injection process. Additionally to the low lethality rate, the 
hearts derived from the second series displayed milder phenotypes than the ones 
obtained from the first injection sequence; ~55% of the hearts showed even no 
phenotype. A possible explanation for the mild phenotypes may be that the stability of 
TSA reached its limit and the efficacy of the inhibitor weakened. 
There was no obvious association between the severity of the phenotype and the 
injected TSA concentration; both concentrations generated the same severity of 
phenotypes. Taking the 17 evaluable hearts of the first and the second injection series 
together, ~35% of the hearts showed no phenotype, in ~41% an atrial hypertrophy (Fig. 
3 & 4) was observable, ~12% displayed a hypertrophy of the right ventricle and in 6% 
respectively ventricular hypertrophy and disturbances in the formation of the outflow 
tract or incorrect positioning of the atria were detected. 2 of the 7 hearts exhibiting an 
atrial hypertrophy showed additional malformations: 1 of these hearts missed the 
ventricular septum and the other one demonstrated an aberrant formation of the 
outflow tract. 
The most prominent phenotypes being detected were aberrant areal proportions of 
atria to ventricles and of left ventricle to right ventricle; these features were measured 
and compared to control hearts, which were either treated with DMSO (solvent of TSA) 
or received no treatment at all. 
As the HDAC inhibitor, DMSO was also transferred into the pericardial cavity via 
implantation of beads soaked in 0.05% DMSO or direct injections being performed with 
a 0.05% and a 0.015% DMSO solution. In total 28 DMSO hearts were evaluated: ~82% of 
these control hearts presented no phenotype (Fig. 5) and ~18% revealed a very mild 
phenotype; 4 hearts displayed an atrial hypertrophy and the ventricles of 1 heart were 
septated inaccurately. The detected phenotypes were not accumulated in one of the 
implantation or injection series; they were distributed regularly.  
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In conclusion, the DMSO hearts demonstrated a very mild phenotype; however, the rate 
and severity of phenotypes observed in the TSA treated embryonic hearts were much 
more pronounced. 
The 7 untreated hearts were used as negative controls; none of them showed an 
aberrant phenotype.  
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Fig. 1: TSA treated embryonic chicken heart at developmental stage HH 27. The heart was exposed to the 
HDAC inhibitor by implantation of 2 heparin-acrylic beads soaked in 165 µM TSA. (a) whole heart, (b-f) 
histological stained sections show deviant proportions of atria to ventricles (atrial hypertrophy). 
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Fig. 2: TSA treated embryonic chicken heart at developmental stage HH 29. The heart was exposed to the 
HDAC inhibitor by implantation of 4 heparin-acrylic beads soaked in 165 µM TSA. (a) whole heart, (b-f) 
histological stained sections show deviant proportions of atria to ventricles (ventricular hypertrophy) and of 
right ventricle to left ventricle (hypertrophy of the right ventricle). 
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Fig. 3: TSA treated embryonic chicken heart at developmental stage HH 26. The heart was exposed to the 
HDAC inhibitor by direct injection of 50 µM TSA. (a) whole heart, (b-f) histological stained sections show a 
mild phenotype of deviant proportions of atria to ventricles (atrial hypertrophy). 
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Fig. 4: TSA treated embryonic chicken heart at developmental stage HH 27. The heart was exposed to the 
HDAC inhibitor by direct injection of 165 µM TSA. (a) whole heart, (b-f) histological stained sections show a 
mild phenotype of deviant proportions of atria to ventricles (atrial hypertrophy). 
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Fig. 5: DMSO treated embryonic chicken heart at developmental stage HH 26. The control heart was 
exposed to DMSO by implantation of 2 heparin-acrylic beads soaked in 0.05% DMSO. (a) whole heart, (b-f) 
histological stained sections show no phenotype. 
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After measuring the areas of the left and right ventricle and of the atria of the TSA and 
DMSO treated hearts and the untreated cardiac tissue, the data were analyzed. 
As previously mentioned, the implantation of TSA beads induced a very local effect, 
which could be clearly recognized on the cardiac tissue; nevertheless, due to that local 
effect, these hearts could not be used for adequate morphometric analysis. The hearts 
of the first injection series were required for determination of the acetylation level of 
TSA treated hearts; thus, the measurement data of the embryonic hearts of the second 
sequence of injections remained to be evaluated. Table 1 shows the mean values of the 
measured and analyzed data. 
 
Treatment of the hearts Atria:ventricles ratio Left ventricle:right ventricle ratio 
TSA 1:1.6 1:1.3 
DMSO 1:2.9 1:1.5 
Untreated 1:2.8 1:1.7 
Table 1: Mean values of the areal ratios of atria to ventricles and of left ventricle to right 
ventricle. The analysis included 4 TSA treated hearts, 3 DMSO treated hearts and 2 untreated 
hearts. 
 
Concerning the atria to ventricles ratio, the TSA treated hearts present a significant 
difference to the DMSO treated and the untreated hearts; in proportion to the atria, the 
ventricles of the control hearts are approximately twice as large as the ventricles of the 
TSA treated hearts. The left ventricle to right ventricle ratio of the TSA treated cardiac 
tissue demonstrates no significant deviation to the values of the control hearts. 
Probably, the mildness of the malformation (being common in the second series of TSA 
injections) and the low percentage representing the addressed phenotype does not 
affect the mean value. 
 
3.2. Analysis of proliferation and apoptosis in the treated embryonic 
hearts 
To exclude the possibility that TSA and/ or DMSO have caused apoptosis in the 
embryonic hearts and that, consequently, the phenotypes have to be attributed to 
apoptotic effects, an apoptosis and a proliferation assay were performed. 
For the BrdU cell proliferation assay, the synthetic nucleoside was administered to the 
embryos 1 h before the hearts were to be removed. After the removal, the hearts were 
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fixed, embedded in paraffin and sectioned; subsequently, the BrdU assay was 
performed. Proliferating cells were labeled with Alexa 488, a fluorescent dye emitting 
green light; after counterstaining with DAPI, the cell nuclei appeared blue under the 
fluorescent microscope. 
The TUNEL assay requires no pre-treatment. Hence, the embryos were removed from 
the eggs and the chicken hearts were fixed, embedded and sectioned before the TUNEL 
assay was carried out. Apoptotic cells were labeled with the fluorescent dye fluorescein 
(FITC), thus, they appeared green under the fluorescent microscope. The cell nuclei were 
again counterstained with DAPI. 
Both assays were performed with sections of the same 11 embryonic chicken hearts 
being derived from the second series of  TSA/ DMSO injections: 3 hearts were treated 
with 50 µM TSA, to 3 hearts 165 µM TSA was administered, 2 hearts had received 0.05% 
DMSO injections and 3 hearts had remained untreated. 
The evaluated regions were the pericardium, the atrial and ventricular myocardia, the 
myocardium of the outflow tract and the endocardial cushions. 
In these examined cardiac tissues autofluorescent erythrocytes were recognized; these 
cells were not included in the analysis.  
The green Alexa 488 signal of the BrdU assay was clearly perceptible in every sample. 
Positive cells were detected in the pericardium and in the endocardial cushions, where 
the signal was distributed almost equally. There were also positive signals detectable in 
the myocardia of the atria and of both ventricles; in contrast to the previously 
mentioned structures, these cardiac tissues showed a locally confined proliferation (Fig. 
6). Comparing the different treated hearts, the intensity of the signal varied only slightly 
from heart to heart. Consequently, between TSA-, DMSO-, and untreated hearts, there 
were no differences in proliferation behavior observable. 
Regarding the TUNEL assay, in all hearts the green fluorescein signal was distinctly 
noticeable in the pericardium and the endocardial cushions (Fig. 7). In some of the 
hearts positive cells could also be detected in the muscular tissues, but they were found 
to be only locally restricted. One heart, treated with 165 µM TSA, showed clearly 
perceptible positive cells for apoptosis in the myocardium of the outflow tract (Fig. 7). A 
minimal positive signal in the atrial myocardium was observed in a 50 µM TSA treated 
heart as well as in one of the DMSO treated hearts. A further slight positive staining was 
identified in the myocardium of the right ventricle of 2 TSA treated hearts (to one of 
these hearts 165 µM were administered and the other one was treated with 50 µM TSA) 
and one untreated heart. In another 50 µM treated heart an even fainter signal could be 
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noticed in the left ventricular myocardium. In short, these locally confined minimal 
signals in the muscular cardiac tissues were distributed throughout the range of 
different treated hearts and were not particularly found in TSA-, DMSO- or un-treated 
hearts; hence, hearts treated with TSA or DMSO were not more apoptotic than 
untreated hearts. 
Comparing these both assays, apoptosis and proliferation did not overlap. In the 
apoptotic regions of the hearts no enhanced proliferation signal was noticed; apoptosis 
was not compensated by increased proliferation in the affected areas. Accordingly, in 
the regions in which a clearly perceptible TUNEL signal was detected, apoptosis was a 
desired developmental effect: At about stages HH 27-31 in chicken development, the 
aortico-pulmonary septum dividing the truncus arteriosus in the aorta and the 
pulmonary artery, is built. During this process, extensive apoptosis and remodelling take 
place in the myocardium of the outflow tract and facilitate the appropriate positioning 
of the great vessels over their particular ventricles. (Bellairs & Osmond, 2005) 
In the endocardial cushions, there could be found clearly noticeable signals for apoptosis 
and proliferation. The high intensity of the signals in the cushions could possibly express 
the remodelling of these structures to septa or valves. The cushions play a vital role in 
heart septation which occurs about developmental stages HH 24-31. (Bellairs & 
Osmond, 2005) The observed hearts were removed from the embryo at stages HH 24-
27. 
Concerning the pericardium, where also distinctly visible signals of proliferation and 
apoptosis were located, it is possible that the performances of the assays were 
responsible for the strongly positive cells. During the incubation of the cardiac tissue 
with the antibodies, coverslips were placed over the sections to prevent them from 
drying; the antibodies maybe accumulated at the marginal structures of the sections 
and, thus, the pericardium became stained at such a high level. 
The performed assays do not allow a quantitative evaluation of proliferation and 
apoptosis in whole hearts. Nevertheless, the information given by the BrdU- and the 
TUNEL assays allow the conclusion that the used concentrations of the HDAC inhibitor 
and its solvent have not severely affected apoptosis or proliferation in the examined 
cardiac tissues. In both assays no significant differences between TSA treated cardiac 
tissues and control hearts were observable. This result confirms the assumption that the 
detected phenotype of the TSA treated hearts (i. e. the deviant areal proportions of atria 
to ventricles) is genuinely a hypertrophy signifying an escalated cell size for the same cell 
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number rather than a hyperplasia, represented by an increased cell proliferation rate 
without expansion of cell size. 
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Fig. 6: Proliferation assay of a TSA treated embryonic chicken heart at developmental stage HH 
27. The heart was exposed to the HDAC inhibitor by direct injection of 165 µM TSA. (a) atrial 
myocardium, (b) endocardial cushions, (c) right ventricular myocardium and pericardium, (d) left 
ventricular myocardium. 
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Fig. 7: Apoptosis assay of a TSA treated embryonic chicken heart at developmental stage HH 27. 
The heart was exposed to the HDAC inhibitor by direct injection of 165 µM TSA. (a) endocardial 
cushions, (b) myocardium of the outflow tract, (c) pericardium. 
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3.3. Analysis of the acetylation level of the treated embryonic hearts 
To be able to determine the acetylation level of TSA-treated hearts, a Western analysis 
was carried out. For comparison, DMSO-treated and untreated embryonic hearts were 
included in the analysis. To maintain the acetylation level of the core histones in the 
nuclei of the cardiac tissue, the chicken embryos being removed from the eggs, were 
immediately placed in sodium butyrate; the subsequently extracted hearts were also 
kept in sodium butyrate. The histones were isolated from the cardiac tissue and 
separated on SDS gels; 82.5 µg of proteins were loaded on each lane in a total volume of 
8 µl. The Coomassie staining of one gel showed that the protein extract contained the 
expected histones and confirmed that the same quantity of each sample was loaded.  
The other gel was used for Western analysis; the separated histones were blotted onto a 
nitrocellulose membrane. The efficiency of the blotting was ensured by Ponceau S 
staining of the membrane. The detection and visualization of the acetylated histones H3 
and H4 was accomplished by immunohistochemistry. 
Western analysis was performed twice, once with embryonic chicken hearts being 
derived from an implantation sequence having used beads soaked in 165 µM TSA or 
0.05% DMSO; the second analysis was accomplished with hearts from the first series of 
injections also having applied 165 µM TSA or 0.05% DMSO to the hearts. 
The first Western blot was carried out with hearts of embryos at developmental stages 
HH 24/25 being gained 6 h after the implantation of beads, and with cardiac tissues of 
embryos at HH 26/27 which were acquired 24 h after the implantation. The analysis of 
this first blot showed no differences in the acetylation level of TSA-, DMSO-, or 
untreated embryonic chicken hearts (Fig. 8). It is supposed that the effect caused by the 
beads was too locally limited to exert influence on the whole heart. 
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Fig. 8: The histone blot shows the cardiac acetylation level of histones H3 and H4 after 6 h and 
after 24 h of reincubation. The hearts were treated with TSA (165 µM) or DMSO (0.05%) releasing 
beads. As negative controls untreated hearts were used. Positive controls for TSA and DMSO 
were isolated from 293-cells. For the loading control α-C-terminal H3 antibody was used. 
 
The second Western analysis was achieved with cardiac tissues of chicken embryos at 
stages HH 26/27 which were gained 24 h after the injections. The Ponceau S staining of 
the nitrocellulose membrane provided information about the efficiency of the blotting 
process. All desired proteins were transferred successfully onto the membrane. 
Nevertheless, the band displaying the histones of the DMSO treated hearts was not as 
intense as the bands showing the histones of the TSA-, and the untreated cardiac 
tissues; apparently, a too small quantity of proteins was loaded on the gel. Hence, the 
band of the DMSO treated hearts was excluded from the analysis; this only concerns the 
DMSO band detected and visualized by the α-AcH4 antibody. Furthermore, difficulties 
were caused during the detection and visualization procedure; the loading control could 
not be performed successfully.  
The analysis of the hearts treated by injections demonstrated no differences in the 
acetylation level of histone H3; the bands of the TSA-, DMSO-, and untreated hearts 
showed the same intensities. As for histone H4, the band of the TSA treated heart 
displays a higher intensity than the one presenting the untreated negative control (Fig. 
9); hence, the hearts to which the histone deacetylase inhibitor was administered 
appear to have a higher acetylation level for histone H4 than the untreated cardiac 
tissues. 
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Fig. 9: The histone blot shows the cardiac acetylation level of histones H3 and H4 after 24 h of 
reincubation. The hearts were treated with TSA (165 µM) or DMSO (0.05%) by injections. As 
negative controls untreated hearts were used. The DMSO band detected by the α-AcH4 antibody 
was excluded from the analysis. The loading control, which should have been performed with α-
C-terminal H3 antibody, failed. 
  
72 
 
4. Discussion 
This study has addressed the role of class I HDACs in cardiac development of the avian 
model organism “chicken” during early embryonic stages. Due to previously performed 
experimentations by Murko and colleagues (2010), the temporal expression patterns of 
Hdacs 1, 2, 3, and 8 in the chick heart were known. Thus, to gain insight into the roles of 
class I HDACs in the cardiac tissue, these enzymes were inhibited by TSA. Subsequent 
histological and morphometric analysis, a proliferation assay as well as an apoptosis 
assay, and the determination of the acetylation level in the chick hearts allowed first 
observations of the phenotypic effects of class I HDAC inhibition in avian cardiac tissue. 
The examined chicken hearts treated with the HDAC inhibitor displayed a range of 
severe phenotypes, such as atrial hypertrophy, ventricular hypertrophy, hypertrophy of 
the right ventricle, malformations of the ventricular septum, and aberrant formation of 
the outflow tract. However, the cardiac tissue showing hypertrophic effects, especially 
atrial hypertrophy, was found to be more pronounced than the other phenotypes. 
It should be noted that TSA also depletes class II HDACs (HDACs 4 to 7, 9, and 10) (Zhao 
et al., 2009); thus, the observed cardiac hypertrophy could also be due to the activities 
of class II HDACs. 
Cardiac hypertrophy, signified by an escalated cell size for the same cell number, is a 
result of cardiomyocytes responding to stress signals; multiple extracellular agonists (e. 
g. α- and β-adrenergic agonists, endothelin, angiotensin, and 5-hydroxytryptamine), 
intensified cardiac workload, cell stretch, and aberrant sarcomeric structure and 
function cause hypertrophic growth of cardiac myocytes. At the cellular level, the 
hypertrophic response is typically characterized by an enlarged size of cardiac cells, an 
intensified protein synthesis, an altered formation of sarcomeres, and reactivation of a 
fetal gene program being responsible for the reduced efficiency of the heart. (Backs & 
Olson, 2006) Stress-induced hypertrophy is meant to compensate ventricular wall stress; 
however, if the hypertrophic growth of cardiomyocytes persists, the subsequent 
enlargement of the heart results in cardiac arrhythmias, heart failure, and sudden death 
(Frey & Olson, 2003). 
The maintenance of appropriate cardiomyocyte size depends on the balance between 
pro- and antihypertrophic pathways (Kook et al., 2003). In general, class I HDACs are 
communicated to repress antihypertrophic genes, whereas class II HDACs are supposed 
to inhibit the expression of prohypertrophic genes (Backs & Olson, 2006; Kook, et al., 
2003). 
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Cardiac hypertrophy is an often reported phenotype caused by experimentations with 
mice. For the lack of studies concerning the model organism “chicken” and the high 
homology between full length proteins of class I HDACs in chicken and mouse (i. e. 
HDAC1 93.1%, HDAC2 97.8%, HDAC3 96.9%, and HDAC8 87.8%) (Murko et al., 2010), it is 
assumed that the already known murine cardiac phenotypes can be inferred on the 
observed hypertrophic effect in embryonic chick hearts. Thus, the possible functions of 
HDACs in the heart of early chicken embryos related to hypertrophy will be discussed by 
reference to the previously detected phenotypes of the mouse heart. 
By using hypertrophic stimuli, Montgomery et al. (2007) found cardiac hypertrophy in 
hearts of 8 to 10 week old mice bearing a cardiac deletion of either Hdac1 or Hdac2 or 
of both genes. However, the observed hypertrophic response of these hearts was 
comparable to the hypertrophic response recognized in the cardiac tissue of wild-type 
littermates (Montgomery et al., 2007). Trivedi and colleagues (2007) also tested 
hypertrophic stimuli on postnatal mice carrying a Hdac2 gene-trap deletion; these mice 
showed no signs of a cardiac hypertrophic response or a reactivation of the fetal gene 
program which is typically associated with hypertrophy of the heart (Trivedi et al., 2007). 
Kee et al. (2008) administered hypertrophic stimuli to hearts of postnatal wild-type 
mice; a raised activity was discovered for Hdac2, but not for Hdac1. Furthermore, the 
activation of Hdac2 to stimuli causing hypertrophy was tested in cardiomyocytes of 
neonatal rats which were transiently transfected with wild-type Hdac2; the application 
of the stimuli to the transfected cardiac cells resulted in an escalated Hdac2 activity. 
HDAC2 was found to induce the expression of atrial natriuretic factor (ANF) which is a 
marker of hypertrophy; cardiomyocytes transfected with wild-type Hdac2 displayed an 
extended cell size and a stress-induced formation of muscle fibers. An enzymatically 
inactive form of HDAC2 failed to activate a hypertrophic response. (Kee et al., 2008)  
HDAC2 was found to interact with the homeodomain-only protein (HOP), which 
regulates cardiomyocyte proliferation and growth. An association of HDAC2 and HOP is 
reported to transcriptionally repress antihypertrophic genes leading to cardiac 
hypertrophy which was observed 3 weeks after the mice’ birth. Overexpression of a 
mutant form of HOP which did not recruit HDAC2 prevented hypertrophy of the mouse 
heart; the deficiency of HDACs caused by inhibitors, such as TSA, also suppress 
hypertrophic pathways. (Kook et al., 2003) Conversely, in mice a cardiac-specific 
overexpression of either Hdac1 or Hdac2 displayed a robust hypertrophy and dilatation 
of the heart inducing lethality (Montgomery et al., 2008; Trivedi et al., 2007). 
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Taken together, these findings support, or at least do not refute, the assumption of class 
I HDACs being repressors of antihypertrophic genes. However, Hdac2 expression was 
not found in the cardiac tissue of the developing chicken embryo (Murko et al., 2010); 
thus, it remains to be elucidated, if the communicted redundancy of HDACs 1 and 2 
enables HDAC1 to compensate for the absence of HDAC2 or if other HDAC related 
mechanisms underlie the hypertrophic response in chicken hearts. 
In contrast to HDACs 1 and 2, HDAC3 is assumed to prevent cardiac hypertrophy. A 
conditional deletion of Hdac3 in a mouse heart resulted in a severe hypertrophy with 
enlarged right and left atria and interstitial fibrosis (designated by fibroblast 
proliferation causing an increased production of collagen) leading to lethality 3 to 4 
month after birth. As for the hypertrophic cardiomyocytes, HDAC3 was found to repress 
the peroxisome proliferator-activated receptor alpha (PPARα) which operates as a 
transcription factor regulating the expression of genes involved in fatty-acid intake and 
metabolism. In Hdac3-deficient murine cardiomyocytes, the acetylation levels at the 
promoters of various PPAR-responsive genes were discovered to be escalated. This 
increased activity of PPAR-responsive genes caused a ligand-induced accumulation of 
lipids within the heart ending in lethality after 3-4 month after birth. In addition, several 
markers indicating cardiac hypertrophy were significantly upregulated and the 
sarcomeric organization was disrupted leading to minimized contractility and 
malfunctioning of the ventricles. (Montgomery et al., 2008) 
The over-expression of Hdac3 in murine cardiomyocytes prevented hypertrophy; 
instead, proliferation of cardiac cells was induced and resulted in enhanced thickness of 
the myocardium (Trivedi et al., 2008). 
In conclusion, compared to HDACs 1 and 2, HDAC3 reveals an exclusive role in the 
progression of cardiac hypertrophy. The actions of this enzyme seem to argue against a 
general role of class I HDACs in repressing antihypertrophic genes in cardiac myocytes. 
HDAC8 was demonstrated to interact with the estrogen-related receptor α (ERRα) in 
vivo; the enzyme enhanced the transcriptional function of ERRα (Wilson et al., 2010) 
regulating genes which encode for enzymes being involved in the maintenance of 
energy balance in animals. In mice ERRα was found to be expressed at a high level in 
cardiac tissue (Ranhotra, 2009; Stein & McDonnell, 2006); ERRα controls numerous 
pathways of mitochondrial energy metabolism in cardiomyocytes (Huss et al., 2007). 
Huss et al. (2007) showed that the expression of the ERRα gene was diminished in 
hypertrophic cardiac tissue of mice 10 to 12 weeks of age; the hypertrophy was 
accompanied by decreased high-energy phosphate supplies and aberrations in glucose 
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metabolism. In hearts deficient for ERRα, genes associated with oxidation of fatty acids 
and glucose and such anticipating in phosphate transfer were negatively affected; 
respiration studies determined a reduced ATP synthesis/O2 consumption ratio in murine 
ERRα-null hearts. (Huss et al., 2007) 
As previously mentioned, HDAC8 heightens the transcriptional activation of several 
genes by deacetylating ERRα (Wilson et al., 2010) which is definitely present in cardiac 
tissue of mice (Ranhotra, 2009; Stein & McDonnell, 2006). If Hdac8 is expressed in the 
mammalian heart remains to be fully elucidated for there exist contradictory 
outcomings (Buggy et al., 2000; Hu et al., 2000; Van den Wyngaert et al., 2000; 
Waltregny et al., 2004). However, in chicken hearts HDAC8 was detected at low levels by 
WMISH (Murko et al., 2010). Hence, it may be possible that HDAC8 plays an indirect role 
in the energy metabolism of avian cardiac tissue via transcriptional regulation of ERRα. 
In that case, a deletion of Hdac8 which leads to reduced activity of ERRα (Wilson et al., 
2010) should be assumed to cause hypertrophic effects as described for ERRα-deficient 
mice; thus, as HDAC3, HDAC8 would not act as repressor of antihypertrophic genes. 
However, if a HDAC8-ERRα-interaction exists in chicken, remains to be elucidated. 
Class II HDACs are believed to suppress postnatal hypertrophy of cardiac myocytes 
(Zhang et al., 2002) by inhibiting expression of prohypertrophic genes (Backs & Olson, 
2006; Kook, et al., 2003). Importantly, class IIa HDACs (i. e. HDACs 4, 5, 7, and 9) are 
reported of being highly redundant (Haberland et al., 2008). 
Hypertrophic response in animal hearts bearing a deletion of a member of the class IIa 
HDAC family is associated with superactivation of myocyte enhancer factor-2 (MEF2) 
(Zhang et al., 2002); a correlation between the transcription factor MEF2 and cardiac 
hypertrophy is proposed (Backs & Olson, 2006). Class IIa HDACs are able to interact 
directly with MEF2 leading to transcriptional repression of genes containing binding sites 
for MEF2 (Backs & Olson, 2006; Han et al., 2005). MEF2 acts as a calcium-dependent 
regulator of cell division, differention, and apoptosis; furthermore, MEF2 represents a 
final target for stress-induced signals in the adult myocardium and is responsible for the 
activation of fetal gene programs in the heart (McKinsey et al., 2002). Concerning 
cardiac abnormalities in mice, HDAC5 and HDAC9 are reported to play essential roles. 
Most of the mice lacking both, Hdacs 5 and 9, show severe aberrations of the heart; due 
to thin-walled myocardium and defects of the ventricular septum the murine embryos 
die during late stages of development. (Backs & Olson, 2006; Chang et al., 2004; 
Haberland et al., 2008) Animals being deficient for either Hdac5 or Hdac9 are viable and 
display no cardiac phenotype at early age; however, at about 6 months after birth, in the 
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mutant mice a hypertrophy of the heart was established spontaneously (Chang et al., 
2004). Mice lacking either of these both enzymes developed a hypersensitivity to stress-
dependent signals, such as caused by age-related cardiac insults. In the myocardium of 
wild-type hearts stress stimuli usually activate the calcineurin (CN) and calmodulin 
dependent protein kinase (CaMK)-protein kinase D (PKD) pathways resulting in 
phosphorylation of the class IIa HDACs; the phosphorylation leads to export of the 
HDACs from the cell nucleus to the cytoplasm. Besides the inactivation of class IIa HDACs 
by nuclear export, a Ca2+/calmodulin (CaM) complex interacts with class IIa HDACs, 
thereby replacing MEF2. Thus, the transcription factor MEF2, which is generally 
suppressed by class IIa HDACs becomes derepressed and activates genes involved in 
cellular growth. In a mouse heart bearing a deletion of either Hdac5 or Hdac9 the 
counter-regulatory mechanism inhibiting hypertrophic response of cardiomyocytes is 
lost; hence, these hearts are hypersensitive to cardiac stress, although the two enzymes 
acquire redundant roles in the repression of cardiac hypertrophy in response to stress-
induced signals. (Backs & Olson, 2006; Chang et al., 2004; Haberland et al., 2008) 
Indeed, class IIa HDAC activity is not restricted to repressing MEF2; class IIa HDACs are 
also able to, directly or indirectly, bind to and inhibit other transcription factors 
associated with the hypertrophic response in cardiomyocytes (Backs & Olson, 2006). 
It is concluded that HDAC5 and HDAC9 repress a distinct subset of hypertrophic signaling 
pathways being based on intracellular calcium signaling (Backs & Olson, 2006; Chang et 
al., 2004). 
Moreover, besides the repression of MEF2 by class IIa HDACs, class I HDACs are also 
recruited to suppress MEF2 target genes. Cabin 1 is a further transcriptional repressor of 
MEF2; Cabin 1 binds MEF2 and inhibits the actions of the transcription factor by 
recruitment of the mSin3 corepressor and its associated HDACs 1 and 2. (Youn & Liu, 
2000) 
In addition, HDAC3 has been found out to control MEF2 activity by directly associating 
and, thus, repressing MEF2 (Grégoire et al., 2007). Furthermore, class II HDACs are 
reported to obtain no intrinsic deacetylase activity; instead, the addressed HDACs 
recruit the SMRT/N-CoR-HDAC3 complex to be able to deacetylate and suppress 
transcription (Fischle et al., 2002). Accordingly, Backs and Olson (2006) consider it likely 
that class II HDACs recruit the deacetylase activity of class I HDACs which enables the 
members of class II HDACs to completely apply their repressive exertion on target genes 
(Backs & Olson, 2006). 
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In short, cardiac hypertrophy is the result of an entangled complexity of stress 
tansmitting signaling pathways in which HDACs are definitely involved (Frey & Olson, 
2003). 
The roles of the other class IIa HDACs (HDACs 4 and 7) and class IIb HDACs (HDAC6 and 
HDAC10) in cardiac tissue remain to be investigated. 
This study has addressed the role of class I HDACs in early avian cardiac development; 
after inhibition of the HDACs by TSA, significant hypertrophic effects in chicken 
embryonic hearts were found in vivo. Hence, class I HDACs, and apparently class II 
HDACs as well, play an important role in cardiac development of early chicken embryos. 
Interestingly, all investigations concerning cardiac malformations in mice report about 
postnatal hypertrophy of the heart, whereas in chicken the cardiac hypertrophic effects 
were already observable at embryonic stages HH26 to HH29 (about 5 to 6 days after 
incubation). Additionally, in the avian model system the most pronounced cardiac 
phenotype was an atrial hypertrophy, not a hypertrophy of the whole heart. However, it 
cannot be ruled out that the enlargement of the atria is only the beginning of a 
hypertrophy of the whole organ; maybe this is a mechanism to maintain efficient 
functioning of the ventricles as long as possible and, thus, prolonging heart failure. 
To gain additional insight into the activities of class I HDACs in cardiac development of 
chicken embryos, further studies have to be performed. Morphometric analysis could be 
extended; the thickness of ventricular and atrial myocardia and septa should be 
measured to be able to discover more phenotypical differences between TSA treated 
and control hearts. The formation of the outflow tract should also be given more 
attention. Another worthy goal is the determination of the spatio-temporal expression 
patterns of class II HDACs in chicken embryos. To be able to distinguish between the 
different roles of HDACs during heart development, the enzymes have to be inhibited 
individually. 
However, the experimentations presented in this study were performed in embryonic 
chicken hearts for the first time. I hope this piece of work provides possibilities for the 
development of novel manipulation procedures regarding the model system “chicken”. 
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